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Driven by the increased performance and availability of protein mass spectrometry 
and next generation sequencing technologies, research in proteomics and systems biology 
has expanded far beyond the study of model organisms. This heralds a deeper 
understanding of biology, the world, and human health. However, it also brings significant 
new challenges to the interpretation of sequencing and mass spectrometry data, the current 
software tools ill-suited for many modern studies. The first half of this dissertation explores 
some of these challenges and solutions in the context of a particularly demanding domain 
– that of serological antibody proteomics. Our team has developed a combined sequencing 
and proteomics approach for profiling the human serum antibody repertoire. This opens an 
unprecedented view into the nature of the adaptive immune system and provides insight on 
antibody repertoire dynamics in both health and disease. The platform also provides 
effective means to evaluate vaccine efficacy and identify potential antibody therapeutics. 
Chapter 1 reviews recent advances in and results from such molecular level 
characterization of the serum antibody repertoire. Detailed in the second chapter, 
challenges specific to antibody repertoire proteomics preclude the use of standard analysis 
methods and motivated our development of novel tools and approaches for interpreting 
serum repertoire proteomic data. I will shift focus in chapters 3 and 4 to present an 
 viii
experimental and computational workflow for accurate and full-length de novo peptide 
sequencing. We applied 351 nm ultraviolet photodissociation (UVPD) on chromophore-
tagged peptides and developed software for sequencing the resultant UVPD mass spectra. 
Improvements described in chapter 4 enable the software to automatically learn from and 
interpret new types and combinations of spectra from the same precursor peptide. We 
demonstrate the effectiveness of this machine learning framework on CID/UVPD spectral 
pairs and obtain results, from low resolution spectra, comparable to current state of the art. 
Continued development of these de novo interpretation and sequencing methods, in part or 
in whole, may sidestep many of the remaining challenges facing repertoire proteomics, and 
successful application of these efforts promises further advancement in antibody repertoire 
characterization and understanding. 
 ix
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Chapter 1: Next-generation sequencing and protein mass spectrometry 
for the comprehensive analysis of human cellular and protein antibody 
repertoires 
Recent developments of high-throughput technologies are enabling the molecular-
level analysis and bioinformatic mining of antibody-mediated (humoral) immunity in 
humans at an unprecedented level.* These approaches explore either the sequence space of 
B-cell receptor repertoires using next-generation deep sequencing (BCR-seq), or the amino 
acid identities of antibody in blood using protein mass spectrometry (Ig-seq), or both. 
Generalizable principles about the molecular composition of the protective humoral 
immune response are being defined, and as such, the field could supersede traditional 
methods for development of diagnostics, vaccines, and antibody therapeutics. Three key 
challenges have driven recent advances: (1) incorporation of innovative techniques for 
paired BCR-seq to ascertain the complete antibody variable-domain VH:VL clonotype, (2) 
integration of proteomic Ig-seq with BCR-seq to reveal how the serum antibody repertoire 
compares with the antibody repertoire encoded by circulating B cells, and (3) a demand to 
link antibody sequence data to functional meaning (binding and protection). 
INTRODUCTION 
Since the landmark discovery of antibody (or immunoglobulin) in blood serum 
more than 100 years ago, we now know conclusively that serum is composed of a complex 
spectrum of distinct antibodies (is polyclonal) which are generated by individual B-cell 
clones through extraordinary modes of genetic recombination, diversification, and 
selection by antigen (antibody generator) according to rules outlined in the paradigmatic 
                                                 
* This chapter draws heavily from [Lavinder, J. J.; Horton, A. P.; Georgiou, G.; Ippolito, G. C. Current 
Opinion in Chemical Biology 2015, 24, 112–120.] and less so from [Wine, Y.; Horton, A. P.; Ippolito, G. 
C.; Georgiou, G. Current Opinion in Immunology 2015, 35, 89–97.]. I contributed writing, research, 
editing, and the illustrations. 
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“clonal selection theory”. Remarkably, however, there had been no way to identify, and 
determine the relative concentrations, of the monoclonal antibodies that compose the serum 
polyclonal pool elicited in response to vaccination or natural infection, until recently.1–3 
Understanding the composition of the antigen-specific serum antibody protein repertoire, 
the properties (e.g. affinities, epitopes recognized) of the respective immunoglobulins, and 
finally, the relationship between circulating immunoglobulin and the presence of clonally 
expanded B cells is profoundly important for the comprehensive understanding of humoral 
antibody responses. 
The current era of modern genomics and proteomics is providing extraordinary new 
tools for examining antibody repertoires. Next Generation Sequencing (NGS) allows 
millions of B cell immunoglobulin sequences to be obtained in a single experiment, and 
NGS approaches to studying the human antibody repertoire4 not only aim to aid in the 
discovery of elite antibodies potentially useful as therapeutics, but also to comprehensively 
catalogue the antibody sequences that are elicited during an adaptive immune response.5 
Previously a limitation with NGS, the ability to obtain the endogenous variable heavy and 
light chain (VH:VL) pairs within NGS datasets is now feasible.1,6 This paired VH:VL 
sequencing represents a major breakthrough in repertoire analysis, obviating the need for 
multiplexed screening to identify functionally paired VH and VL. NGS has also provided 
a stepping stone to the direct characterization of serum antibodies using NGS database-
driven high resolution mass spectrometry,1–3,7 providing a direct means to comprehensive 
delineation of the antibody repertoire. 
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TWO ANTIBODY REPERTOIRES:  THE CELLULAR AND THE SEROLOGICAL  
B cells, serum immunoglobulin, and antibody repertoire persistence 
Antibody molecules are composed of two heavy (H) and two light (L) chains, and 
antigen binding specificity is determined by the variable region of the antibody (or B cell 
antigen receptor, BCR) gene. This region is not coded for in the germline genome but arises 
through V(D)J recombination, a process through which one each of V, (D) and J germline 
gene segments are selected from a combinatorially enormous pool and joined together 
(Figure 1.1). The heavy chain variable region (VH) contains a VDJ junction, and 
nucleotides are added or removed in the V-D and D-J joining sites at random. The CDRH3 
(complementary determining region 3, heavy) spans the D segment and flanking junctions 
and is the primary determinant of antibody specificity as well as the most variable part of 
an antibody molecule. The light chain VL region arises through a similar process of 
recombination of V and J segments. Interspersed between the CDRs (of which there are 
three in both the VH and VL chains) are the highly conserved framework regions (FR). 
Further antibody diversity develops through somatic hypermutation (SHM) of the CDRs 
during affinity maturation, whereby a single B cell lineage may branch out into a multitude 
of clonally related but distinct B cells.8,9 Antibodies secreted from clonally related plasma 




Figure 1.1: Generation and composition of the antibody and B cell repertoires. 
Whereas all newly formed B cells express antibody on their surface as BCR, and 
subsequently emigrate from their generative site in bone marrow to seed the periphery, it 
is only a small minority that might ultimately differentiate during the course of an immune 
response to become memory B cells (mBCs) and an even smaller fraction that secrete their 
BCR as soluble antibody. In this regard, we can conceive of the functional antibody 
repertoire as consisting of two major components: (1) the set of BCRs expressed on the 
surface of B lymphocytes, and (2) the collection of soluble Ig found in blood and secretions, 
produced predominantly (>95%) by terminally differentiated plasma cells in the bone 
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marrow (PCs, BMPCs) (Figure 1.1).10 Humoral immunity against pathogens can be 
sustained for greater than a half century, requiring steady-state expression of serum 
antibodies that are believed to be maintained by long-lived BMPCs.10 However, bone 
marrow specimens are often impractical to obtain in humans, and the vast majority of 
studies that examine the human antibody repertoire interrogate peripheral plasmablasts 
(PBs), circulating mBCs, or all peripheral blood mononuclear cells (PBMCs). 
In summary, the two major components of the antibody repertoire—the quiescent 
mBC cellular and the plasma cell-secreted serological—are both generated during a 
primary response to antigen and persist for sustained yet indeterminate life spans. It is 
therefore reasonable to ask what degree of overlap is present in the molecular composition 
of these compartments. If they are not congruent, as there is reason to think,9 then what 
might be the selective mechanisms that govern their differential recruitment, and what 
might be the consequences to protective humoral immunity? 
Antibody Serology 
The essence of serological immunity is predicated on the existence of a diverse 
repertoire of antibodies, elicited over the life of the host and representing the integrated 
response to numerous antigenic stimuli. Due to the complexity and temporally dynamic 
nature of the antibody repertoire, the identification of its component immunoglobulins 
represents a formidable challenge. Since antigen can trigger B cells to proliferate, mutate, 
and expand, it is a useful metric to enumerate the clonotypes. In the classical sense, a 
clonotype is defined as a repertoire of unique B-cell specificities,11 and serological studies 
to date have relied on the detection of an ensemble of antibodies that either could be 
resolved by a certain analytical technique or bound to a specified antigen (Figure 1.2). 
Among the most useful metrics for assessing humoral immunity, the presence of 
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neutralizing antibodies in the serum following vaccination or infection represents the best 
correlate for vaccine efficacy and for protection during invasive infections.12,13 The 
limitations imposed by the inability to resolve complex serum antibody mixtures into their 
constituent clonal representatives and the need to have pre-established the identity of 
antigens of potential interest have obscured central questions of profound basic and clinical 
significance. 
First and foremost, there is nearly no information on the number of sequences 
(clonal diversity), functions and relative concentrations of the individual antibodies in 
serum. Considering that the BCR repertoire diversity in the memory and plasmablast 
compartments is orders of magnitude greater than that of the serological repertoire1 it 
follows that the overwhelming majority of peripheral B cell-encoded antibodies are 
unlikely to be present in detectable amounts as soluble proteins in blood or secretions and 
thus do not contribute to humoral immunity. Second, while it is well established that a 
significant fraction of antibodies display polyreactivity and that these antibodies have 
important physiological functions in processes such as the clearance of cell debris and in 
pathogen recognition,14 there is a paucity of methods for quantifying and characterizing the 
polyreactive fraction of the serological response. There is a clear need to understand the 
mechanisms that drive polyreactivity and its implications in health and disease. One 
possible explanation is that polyreactivity originates from B cells that were not removed 
from the repertoire during B-cell development. For some pathogens, notably HIV, 
polyreactivity may confer a selective advantage to pathogen–specific antibodies.15 Third, 
in many instances the antigens that are recognized by serum antibodies are not known a 
priori. The significance of identifying antigens, antigen surrogates (i.e. antigen-mimics 
distinct from the antigens that elicited an antibody response) and immunosignatures for 
disease diagnosis is being increasingly recognized.16 Additionally, mapping the serum 
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antigen reactivity profile in a comprehensive manner is key to understanding which 
environmental exposures play a more dominant role in shaping humoral immunity. 
Figure 1.2: Approaches for the analysis of human antibody repertoires. 
B cell high-throughput sequencing generates the antibody repertoire encoded by B cells 
(cellular repertoire, left side of the figure). The corresponding serum immunoglobulins are 
isolated from the samples and can be analyzed by various methods including well 
established technologies such as 2D gels or by recently established methodologies such as 
high resolution shotgun proteomics (serological repertoire, right side of the figure). The 
methodologies for serological immunoglobulin analysis can be broadly based upon the 
phenotype of an antibody subpopulation (e.g., ELISA titer of antigen-specific fraction) or 
upon decipherment of the molecular identity and sequence determination of an antibody 
subpopulation (e.g., LC–MS/MS immunoglobulin sequencing, Ig-seq). 
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Defining the Cellular and Serological Antibody Repertoires 
The earliest and still most common NGS-enabled studies of the repertoire have 
focused on the CDR-H3 region—its length, peptide sequence, and IGHV and IGHJ gene 
usage patterns—to define heavy chain clonotype dynamics. CDR-H3 clonotypes, defined 
in this regard, typically share the same inferred germline IGHV and IGHJ, CDR-H3 length, 
and have ≥90% peptide sequence homology. A recent and significant innovation in NGS 
is the development of methods to maintain the correct pairing of the VH and VL in the B-
cell repertoire.6,17–19 This is achieved through single-cell sorting, VH:VL linkage PCR 
performed in an emulsion or single-cell wells, and NGS. With regard to clonotyping 
methods, this technological advance will allow more accurate assignment of the complete 
VH:VL antibody clonotype and can additionally take account of important features in VL 
domains. 
Until recently determining the sequence and relative concentration of the antibodies 
in the serum repertoire was considered a nearly impossible task: biological fluids contain 
many thousands of different antibodies all of which are chemically very similar, having an 
overall high degree of sequence identity, and whose concentrations can vary by several 
orders of magnitude in a dynamic fashion. 2008 saw the first use of LC-MS/MS for serum 
immunoglobulin peptide detection.20,21 However, the Ig-derived peptides detected in these 
earlier studies, were overwhelmingly derived from the framework regions and did not 
provide sufficient information to piece together complete antibody sequences. By 
restricting the diversity of the antigen-specific antibody pool from the serum of immunized 
rabbits using antigen-affinity chromatography under stringent elution conditions, 
Polakiewicz and coworkers succeeded in using LC-MS/MS with NGS to identify complete 
V genes. Combinatorial pairing of separate identified VH and VL sequences was then used 
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to produce several antibodies displaying high affinity for antigen, first from rabbits and 
subsequently from humans.3,22 
In an alternate approach, our lab independently invented a technology for 
determining the serological repertoire to individual antigens (Figure 1.3). This combined: 
(i) V gene sequencing from peripheral memory B cells and plasmablasts; (ii) enrichment 
of the pool of antigen-specific antibodies by affinity chromatography; (iii) identification of 
immunoglobulin peptides using bottom up LC-MS/MS and searching against the V gene 
sequences; and (iv) the application of stringent informatics filters and in silico clonotype 
estimation to identify antigen-specific VH genes from the peptide assignments.2,7,23 
Comparison to the natively paired VH:VL sequence repertoire could then reveal the 
complete antibody sequence, which then could be produced and studied in vitro. Thanks to 
the exquisite sensitivity of modern MS instrumentation, individual serum antibodies can 
be detected semi-quantitatively at levels as low as 0.4 ng/ml.1 For an antibody to bind to 
antigen it has to be present at a concentration at or above its equilibrium dissociation 
constant, which is estimated to have a floor of around 0.1 nM.24 Thus, the approach outlined 
above has more than adequate sensitivity for the detection of the repertoire of 
physiologically relevant antibodies in a sample. 
 10
Figure 1.3: NGS and MS analysis of human antibody repertoires from peripheral blood. 
The functional antibody repertoire consist of two major components: (bottom) the total set 
of BCRs expressed on the surface of peripheral blood B cells, and (top) the collection of 
soluble serum antibody circulating in the blood. The ability to compare and functionally 
characterize these two types of antibody repertoires provides a new paradigm in the study 
of the humoral response. This involves the isolation and proteomic analysis of affinity 
purified serum antibody (lg-seq, top) in parallel with VH:VL pairing and/or NGS of 
peripheral B cell V gene repertoires (BCR-seq, bottom). The bioinformatic analyses of 
both the diversified cellular humoral immune response and the endpoint serological 
antibody response provides an avenue for effective antibody discovery, exhaustive 
antibody repertoire characterization, and an improved understanding of humoral immunity.
GENERALIZABLE PRINCIPLES FROM NORMAL ANTIBODY REPERTOIRES 
Natural variation within the primary repertoire 
Because of the sheer size of the human antibody repertoire, estimates of breadth 
and diversity become limited by sampling and only recently have such statistical 
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approaches become feasible. In one study, the total human peripheral B cell repertoire size 
was estimated to contain ~106-107 unique CDR-H3.25 However, the theoretical sequence 
space of the repertoire far exceeds the antibody diversity found within an individual at any 
one point in time, and shared antibody sequences are extremely uncommon.26–28 Yet, at a 
broader level, the overall usage of germline IGHV, IGHD, and IGHJ segments is observed 
to be unequally distributed, yet at a very consistent ratio among individuals, indicating a 
measured amount of determinism in the generation of primary antibody diversity.25 It was 
subsequently shown that this determinism likely arises from genetic factors intrinsic to 
human B cells.29–33 
Unlike the antigen-specific mBC repertoire, which is very diverse and in the case 
of chronic or repeated infections can comprise millions of distinct clones and a much larger 
space of unique VH sequences, the serological repertoire is orders of magnitude more 
restricted. There is indirect evidence that these compartment also differ in humans.9 
Likewise, comparison of the antigen-specific VH gene repertoire of transient PB cells with 
the steady state serological repertoire (in other words, the serological memory) has revealed 
that a very small fraction of the CDR-H3 clonotypes encoded by peripheral B cells are 
observed in the polyclonal serum response (<5% of the CDR-H3 clonotypes in the peak 
response PB repertoire and <0.1% in the steady-state peripheral mBC repertoire).1 
The dramatic discordance between humoral immunity and the VH gene repertoire 
in antigen-stimulated peripheral B cells is not widely appreciated but it can be readily 
illustrated with a simple quantitative analysis of humoral immunity. For circulating 
antibodies to be physiologically relevant, they have to be present in serum at concentrations 
exceeding their equilibrium binding constant, KD. Assuming an average KD of IgGs to 
persistent antigen exposure or re-stimulation of 1-5 nM (or approx. 0.2-1.0 μg/ml) and 
given that serum titers to pathogens rarely exceed 100 mg/ml it follows that the diversity 
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of physiologically relevant antibodies present in the serological repertoire must be of the 
order of 102- 103 (100 μg/ml divided by 0.2-1 μg/ml), or 3 or more orders of magnitude 
smaller than the typical antigen-specific peripheral mBC repertoire. With regard to 
an upper bound, the total serological antibody repertoire could be as large as 106 distinct 
binding specificities (clonotypes).34 This argument assumes that (1) the lowest Ab 
concentration required for the elimination of antigen ~ 10 ng/mL, (2) there is 10 mg/mL 
total IgG in serum, and (3) each distinct Ab is present at threshold concentration. Even at 
106, this still places the serological repertoire at least 101 smaller, perhaps 103 smaller, than 
the cellular repertoire by lower-bound NGS estimates.25 Proteomic analyses from our lab 
estimate IgG clonotypic diversity of ≥104. The discrepancy between the peripheral mBC 
(and also the antigen-specific peak response PB repertoire) and the serum antibody 
repertoire argue strongly that determination of the serological repertoire is critical for a 
comprehensive understanding of antibody- mediated protection mechanisms. 
GENERALIZABLE PRINCIPLES FROM VACCINE-INDUCED ANTIBODY REPERTOIRES 
BCR-seq of vaccine-specific VH antibody repertoires 
Almost all vaccines confer immunity through the induction of antibodies in serum 
or in mucosal tissues.12 Systematic analysis of the antibody-mediated humoral immune 
response to vaccination at high-throughput requires experimental distinction between the 
vaccine-specific and the total antibody repertoire in an individual. One approach to 
inferring antigen specificity is to examine the dynamics in the peripheral B cell repertoire 
before and after vaccination. Jackson et al. showed a direct correspondence between the 
number of clonally expanded peripheral B cell lineages at day 7 post-vaccination and an 
increase in serum titer.35 Jiang et al. similarly used antibody dynamics before and after 
vaccination to identify expanded vaccine-specific antibody lineages within the peripheral 
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B cell repertoire.36 They found that 11 of 16 confirmed influenza-specific VH sequences 
mapped to the expanded lineages. Further, lineage structure analysis revealed that elderly 
patients have fewer, more highly mutated IgG lineages as compared to younger patients. 
Wu et al. also detected higher IgG mutation in the elderly after influenza vaccination, as 
well as significantly longer CDR-H3 in the IgM and IgA lineages that were expanded at 
day 7 post-vaccination.37 Clearly, these studies and others indicate the significance of 
antibody diversity and CDR-H3 characteristics to the humoral immune response and 
support the use of such metrics for studying vaccine efficacy.38,39 A refinement of these 
metrics will include a transition from VH-only BCR-seq to BCR-seq of complete VH:VL 
clonotypes, as well as a quantitative exploration of their absence or presence in the 
serological repertoire using Ig-seq. 
BCR-seq of vaccine-specific paired VH:VL antibody repertoires 
Other, more conventional methods for distinguishing antigen specificity include the 
labeling of antigen-specific mBCs or the isolation of bulk PBs using flow cytometry.40 For 
a variety of viral infections and most immunizations, the appearance of vaccine-specific 
PBs is strikingly consistent in that they peak in number at approximately one week post-
vaccination, or day 10 for primary vaccinations.41 This “plasmablast signature” and its 
predictive capacity for the magnitude of antibody production has been observed by several 
research groups;42,43 how this might relate to the functional quality or exact molecular 
nature of the endpoint serological antibody response is unknown and has yet to be 
comprehensively examined, but current investigations are very tantalizing.35 
As but one example, DeKosky et al. isolated tetanus toxoid (TT) specific PBs on 
day 7 post-vaccination and, using emulsion linkage PCR and NGS from 200 sorted cells, 
identified 86 TT-specific antibody VH:VL pairs in a single experiment.6 A significant 
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improvement in throughput utilizes a newly-developed, low-cost single-cell emulsion-
based technology which flows B cells through a vibrating nozzle to encapsulate individual 
B cells in lysis/PCR reaction droplets that contain magnetic beads for mRNA capture.17 
VH:VL amplicons generated through subsequent emulsion RT-PCR are used for 2 x 300 
Illumina MiSeq NGS. This method increases the B-cell VH:VL yields 100X, to >2x106 B 
cells per experiment with demonstrated pairing precision >97%. This orders-of-magnitude 
increase in B-cell throughput and VH:VL sequencing depth potentially obviates an explicit 
need for antigen-specific cell sorting because literally millions of B-cells can be processed 
and interrogated in a single experiment by a single experimentalist. Thus, an advantage of 
this method is that it allows complete sequencing of all antigen-specific B-cells within a 
finite collected pool (e.g., day 7 PBs or total mBCs at 14 days post-booster vaccination).40 
Serum antibody proteomics (Ig-seq) of vaccine-specific antibody repertoires 
It is now also possible to identify affinity-purified serum antibodies using high-
resolution proteomics.1–3,7 The goal of serum antibody proteomics, or Ig-seq, is to 
systematically identify the distinct antibodies present in a serum sample, as assayed using 
protein tandem mass spectrometry (Figure 1.3). In a study of the immune response to 
tetanus toxoid (TT), Lavinder et al. exhaustively characterized the constituent serum 
antibodies elicited by a vaccine and discovered that the steady state anti-TT serum IgG 
repertoire is composed of a limited number of antibody clonotypes (80-100), with three 
clonotypes accounting for >40% of the response.1 Only a small fraction (<5%) of TT-
specific, vaccine-responsive PBs at day 7 were found to encode antibodies that could be 
detected in the serological memory response 9 months post-vaccination. This suggests that 
only a minority of the antigen-specific, transient PBs give rise to bone marrow long-lived 
plasma cells (BMPCs). This result is not altogether unexpected since huge variability in 
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both the number, kinetics, and the antigen-specificity of transient PBs has been repeatedly 
observed for a variety of vaccination and natural infection contexts.44 This is also in 
agreement with previous data demonstrating that only a fraction (5-10%) of responding 
PBs migrate to the bone marrow after vaccination.45 These differences in the peak 
responding PBs and the effective levels of serum antibodies is a significant finding in that 
the antigen-specific repertoire in vaccinated humans is typically assessed by DNA 
sequencing of these responding PBs, a large number of which do not constitute the post-
boost steady-state antigen-specific serum IgG repertoire. 
Molecular convergence of antibody responses 
Lastly, in the course of the TT study summarized above, we discovered a VH 
clonotype shared between two donors (a stereotype) and also with a third donor analyzed 
independently in a distinct laboratory,46 providing intriguing evidence for the existence of  
“public” clones, or “convergent immune signatures,” emerging after antigen challenge. 
NGS deep sequencing of VH repertoires has discovered the emergence of stereotyped 
serological clones in other vaccinations, such as seasonal influenza H1N1 vaccination35 
and Dengue viral infection,47 and would in principle be detected by the methodology 
developed here. The convergent detection of stereotyped or “public” serum clonotypes 
detected by Ig-seq might correlate strongly with vaccine efficacy, seroconversion, or the 
production of neutralizing antibodies. 
With certain antigens, convergence has been shown to be quite prevalent, producing 
CDR-H3 lineages that are universally identified across individual antibody repertoires. 
Vollmers et al. developed a NGS barcoding technique that uniquely identified each starting 
VH or VL transcript.26 This allowed consensus-based filtering of sequencing error to allow 
an accurate measurement of the memory recall response to vaccination. It also provided an 
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accurate measurement of antibody repertoire convergence, revealing that 25 of ~100,000 
VH sequences were shared between vaccinated individuals. However, all of these were of 
low abundance and had very low amounts of mutation and short CDR-H3, indicating 
stochastic overlap within the naïve B cell repertoire. Jackson et al., however, identified the 
molecular convergence of an antibody response to influenza H1N1 vaccination when 
comparing data with H1N1-vaccinated donors from two additional studies, revealing a 
stereotypic VH lineage that utilized the same V segment, J segment, and highly identical 
CDR-H3s;35 although a striking result, it remains to be determined if this stereotyped 
rearrangement exists not merely as a VH-only but also as a VH:VL clonotype, and whether 
this clonotype exists in the serum antibody repertoire or can be correlated with 
seroconversion and viral neutralization. It is not entirely known how common stereotypic 
B cell responses are in vaccines. However, as detailed below, shared antibody sequences 
have enormous significance as potential biomarkers in both infectious disease and 
autoimmunity.16 
THE ANTIBODY REPERTOIRE IN THE DISEASE STATE 
Infectious disease 
Broadly neutralizing antibodies (bNAbs) directed against HIV and influenza 
viruses have been identified via the cloning of antibody V genes from peripheral B cells 
isolated from infected patients that displayed neutralizing serum titers.48–50 Sequence 
analyses of bNAbs and homologous V genes of antigen-specific cells from the individual 
from which the bNAbs had been isolated, are providing insights on the evolution of broadly 
protective B cell immunity, on preferential usage of certain germline V genes, on somatic 
hypermutation patterns, and other features of neutralizing immune responses. 
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The significance of the information gained from these studies notwithstanding, it is 
not clear whether peripheral B cell-encoded bNAbs actually play a dominant role in the 
serological protection against infection in vivo. As discussed above, serological immunity 
is overwhelmingly contributed by BMPCs, which are often experimentally inaccessible in 
humans. Nonetheless, it should be appreciated that it is the cells of the BMPC compartment 
and not peripheral B cells, which actually secrete the Ig that maintains long-term 
serological memory. So far, it has not been ascertained whether bNAbs isolated from 
peripheral mBCs are actually present in the serum at all, let alone at physiologically 
relevant concentrations (i.e. above KD) as is required in order for these antibodies to play 
a role in virus elimination and protection in vivo. 
The most compelling examples of bNAb functionality is from convergent humoral 
responses that occur within chronic HIV infection. It is known that up to 25% of individuals 
with advanced HIV can develop bNAbs against the virus. NGS is now being used to track 
antibody and viral co-evolution, and the identification of elite bNAbs is now central to the 
study of HIV.51 One of these bNAbs, VRC01, is specific to the CD4 binding site of gp120 
and can cross-neutralize ~90% of HIV-1 isolates. Like many other identified HIV-specific 
antibodies, it shows striking amounts of affinity maturation (70 amino acid differences 
from germline). Wu et al. isolated VRC01-like antibodies from separate HIV-1 infected 
donors using FACS sorting against a CD4-binding site probe.52 NGS and phylogenetic 
analysis of both donors revealed similarities between the affinity maturation pathways for 
the VRC01-like antibodies and demonstrated how NGS data can be used to identify large 
clades of antibody sequences based upon selective criteria, such as V(D)J usage, amount 
of mutation, and sequence identity to known monoclonal antibodies. 
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Autoimmunity and cancer 
Autoantibody repertoires likely contain a wealth of information both in regards to 
the early diagnosis of immunopathology, as well as providing an increased understanding 
of disease progression. Unfortunately, very little is known regarding these potentially 
significant sources of biomarkers. In a pair of recent studies on patients with multiple 
sclerosis (MS), expanded B cell clonotypes in the periphery (peripheral blood in one study 
and cervical lymph nodes in the other) were overlapping with B cell sequences found in 
the CNS of the patient.53,54 It was shown that the founding members of these overlapping 
clonotypes were prevalent in the cervical lymph nodes and that overlapping members in 
the peripheral blood were primarily class-switched B cells. In addition to cross-tissue 
overlap, convergence has also been detected in the autoantibody response. Doorenspleet et 
al. used NGS of B cells from peripheral blood and joint synovial fluid from patients with 
early and establish rheumatoid arthritis (RA), demonstrating potential convergence in the 
dominant B cell lineages within synovial fluid of early RA patients.55 These dominant 
lineages heavily utilized the V segment IGHV4-34 and had significantly longer CDR-H3. 
A few recent studies have also used high-resolution mass spectrometry to proteomically 
identify molecular signatures in the autoreactive antibody response to the Ro/La 
ribonucleoprotein complex in patients with Sjögren’s syndrome (SS).56–58 Although these 
studies only identified a handful of public (shared) antibody lineages and V gene mutations 
across SS patients, it highlights the great potential of serum antibody proteomics in 
autoimmune biomarker discovery. 
Similarly, the antibody response to tumor-associated antigens can provide early 
diagnostic cues in detecting malignancy.59 A series of studies have utilized NGS, as well 
as serum antibody proteomics, to facilitate the early detection and monitoring of Non-
Hodgkin’s lymphoma,60 leukemias,61,62 and multiple myeloma.63,64 Typically, these 
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lymphocyte malignancies are detected and monitored via PCR specific to the malignant 
lineage(s), which requires patient-specific primers to examine values of minimal residual 
disease (MRD). There is great potential for NGS and serum antibody proteomics in 
developing further metrics for diagnostic and prognostic applications in both autoimmunity 
and cancer. 
CONCLUSIONS 
NGS has revolutionized the manner in which we study adaptive immunity, 
providing millions of sequence reads from an enormously complex repertoire of 
lymphocytes. However, these gigantic data sets have an inherent interpretability problem 
in that the sequences specific to “your favorite antigen” are metaphorical needles in a 
haystack. Determining the functionality of the Ig reads obtained in BCR-seq is an 
enormous challenge, and it has now become a common appeal in the field to link function 
with sequence.65,66 As discussed above, in certain cases, convergence or dynamics within 
BCR repertoires can often lead the discovery effort for antigen-specific clonotypes in 
response to vaccination or infection. However, this is not a generalizable strategy and such 
obvious levels of dynamics or determinism may be restricted to certain antigens or only 
evident in cases where the humoral response is robust or ongoing. 
The recent development of paired VH:VL BCR-seq and Ig-seq represent a new 
paradigm of antibody discovery in which functionality (binding) is directly linked to NGS 
of natively-paired antibody gene sequences. This ability to quickly link paired NGS data 
and antibody functionality is a key step forward in antibody discovery and repertoire 
analysis. Not only is this applicable to the vaccine-elicited antibody repertoire, but it also 
enables the link between antibody sequence and function to be ascertained in infectious 
disease, as well as autoimmunity and cancer. 
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Chapter 2: Proteomic Identification of Monoclonal Antibodies from 
Serum 
Characterizing the in vivo dynamics of the polyclonal antibody repertoire in serum, 
such as might arise in response to stimulation with an antigen, is difficult due to the 
presence of many highly similar immunoglobulin proteins, each specified by distinct B 
lymphocytes.* These challenges have precluded the use of conventional mass spectrometry 
for antibody identification based on peptide mass spectral matches to a genomic reference 
database. Recently, progress has been made using bottom-up analysis of serum antibodies 
by nanoflow liquid chromatography/high-resolution tandem mass spectrometry combined 
with a sample-specific antibody sequence database generated by high-throughput 
sequencing of individual B cell immunoglobulin variable domains (V genes). Here, we 
describe how intrinsic features of antibody primary structure, most notably the interspersed 
segments of variable and conserved amino acid sequences, generate recurring patterns in 
the corresponding peptide mass spectra of V gene peptides, greatly complicating the 
assignment of correct sequences to mass spectral data. We show that the standard method 
of decoy-based error modeling fails to account for the error introduced by these highly 
similar sequences, leading to a significant underestimation of the false discovery rate. 
Because of these effects, antibody-derived peptide mass spectra require increased 
stringency in their interpretation. The use of filters based on the mean precursor ion mass 
accuracy of peptide-spectrum matches is shown to be particularly effective in 
distinguishing between “true” and “false” identifications. These findings highlight 
                                                 
* This chapter has been previously published in: Boutz, D. R.; Horton, A. P.; Wine, Y.; Lavinder, J. J.; 
Georgiou, G.; Marcotte, E. M. Analytical Chemistry 2014, 86 (10), 4758–4766. 
D.R.B, A.P.H., and Y.W. contributed equally. 
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important caveats associated with the use of standard database search and error-modeling 
methods with non-standard datasets and custom sequence databases. 
INTRODUCTION 
The ability of the humoral immune system to provide broad protection against a 
diverse and constantly changing population of invasive pathogens stems largely from the 
antigen-binding capabilities of the antibody (immunoglobulin, Ig) repertoire. Antibodies 
recognize foreign molecules (antigens) through epitope-binding sites in the variable 
domains of the antigen binding fragment (Fab), and alert immune cells to putative threats 
through interaction sites in the constant domain of the tail region. Individual antibodies 
will preferentially bind a particular antigenic epitope, with specificity largely determined 
by the antigen-binding site sequences in the variable domains of immunoglobulin heavy 
chain (VH) and light chain (VL) genes. In order to provide coverage against a large variety 
of potential antigens, the B cell-encoded antibody repertoire is incredibly diverse, 
estimated to comprise >108 immunoglobulins with distinct variable domain sequences in 
human serum,67,68 resulting in an antibody population capable of binding a broad range of 
antigens with high affinity and specificity. 
This massive diversification of sequence is the product of two processes: V(D)J 
recombination during B cell maturation, and somatic hypermutation during B cell affinity 
maturation.69 In the heavy chain specifically, the variable domain is generated by 
recombination of V, D, and J gene segments, with a single subgene of each segment 
selected from multiple variants encoded in the germline genome (Figure 2.1). Two of the 
three hypervariable loops responsible for antigen-binding (CDR-H1 and CDR-H2) are 
encoded within the V gene segment, while the third (CDR-H3) is largely non-templated 
and is constructed by the addition of random nucleotides (N-nucleotides) between the 
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recombination joints of the V, D, and J segments.69,70  V(D)J recombination generates a 
single pair of VH and VL genes per B cell, such that every B cell expresses only one 
antibody variant. Somatic hypermutation during humoral immune response fine-tunes 
affinity for antigen by introducing additional mutations in the variable domain, further 
increasing the sequence variation and in turn expanding the sequence diversity within a 
clonotype.9 Consequently, antibodies that originate from the same B cell precursor lineage 
are designated as belonging to the same clonotype and generally exhibit specificity for the 
same antigen.71 
Figure 2.1: Schematic of the structure and representative sequences of the 
immunoglobulin (Ig) heavy chain variable domain. 
The heavy chain variable domain (VH) sequence is created by recombination of V, D, and 
J subgenes and encodes epitope binding sites for antigen-recognition. Complementarity 
determining regions (CDRs) represent uniquely non-degenerate fingerprints, interspersed 
between constant framework sequences (FRs), and manifest as hypervariable and 
conserved sequences, respectively, in the multiple sequence alignment. Antigen binding 
specificity is primarily dictated by the CDR-H3 region. Hence, the challenge of antibody 
repertoire proteomics can be largely reduced to the problem of successfully identifying 
CDR-H3-containing peptides. 
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The process of Ig diversification has been elucidated, and methods for the 
identification and expression of monoclonal antibodies, including creation of hybridomas, 
immortalization of B lymphocytes, and cloning of antibody genes from primary 
lymphocytes, have revolutionized diagnostics and expanded our understanding of how 
immune responses induce the production of circulating antibodies that help clear a 
pathogen. Recently, next-generation (NextGen) sequencing has made possible 
investigations of the scope and sequence composition of the antibody repertoire, as 
represented in the population of B cells sequenced.72,73 With technical and financial barriers 
to personalized sequencing substantially dropping with advances in NextGen technologies, 
immune-related repertoire sequencing is becoming more commonplace.26,74 However, the 
B cell repertoire includes many sequences which are not represented in the circulating pool 
of serum immunoglobulins. Characterization of the polyclonal serum response thus 
requires direct observation of the constituent monoclonal antibodies present at functionally 
relevant concentrations. 
Unfortunately, the proteomic analysis of serum immunoglobulins by mass 
spectrometry (MS) presents several challenges. One such challenge arises from the fact 
that antibody genes are not encoded in the germline but are assembled via DNA 
recombination and diversified within individual B cells. As a result, the typical strategy of 
constructing a reference database from the genome sequence is not useful for interpreting 
antibody-derived mass spectra.21,75 The use of de novo peptide sequencing for mass spectral 
interpretation does not require a reference database,76,77 thus offering a promising solution 
to this problem. Current methods are not yet capable of handling the complexity of peptide 
sequence diversity present in serum. With further development, the de novo workflow we 
present in chapter 4 could potentially suffice. However, a reference database would still be 
necessary to identify full-length VH sequences. 
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A strategy has recently emerged which largely overcomes these barriers by utilizing 
high-throughput sequencing of the immunoglobulin variable domain (V gene) from an 
individual’s B cell population to construct a sample-specific antibody sequence database 
for the interpretation of antibody-derived mass spectral data.3,7,78 With the ability to 
generate a personalized reference database it is now possible to apply shotgun-style MS 
proteomics to the analysis of serum antibodies, as demonstrated by recent studies 
identifying antigen-specific monoclonal antibodies directly from serum.1,3,7,22 Yet even 
with the availability of such a database, confident identification of monoclonal antibodies 
is not trivial. The high degree of sequence identity shared across antibodies introduces 
additional complications in sequence-to-spectrum assignments and protein inference, 
making proteomic analysis of the repertoire particularly challenging. 
The complexity of the V gene repertoire can best be understood as a massively 
expanded set of homologous proteins, each sharing regions of highly conserved (or 
identical) sequences with short intervening hypervariable sequences.  From a proteomics 
perspective, this creates a large pool of potential peptide sequences with at least partial 
sequence identity. Proteolytic digestion of antibodies for shotgun proteomics yields many 
peptides that map to multiple clonotypes and are therefore non-informative for monoclonal 
antibody identification, or that share partial sequence identity with many other candidate 
peptides, resulting in highly similar mass spectra that are difficult to interpret 
unambiguously, even with the high resolution and mass accuracy of current mass 
spectrometers. 
In this paper, we detail how these interspersed segments of variable and conserved 
amino acid sequences create unusual features in the corresponding antibody peptide mass 
spectra. We demonstrate the importance of using high mass accuracy liquid 
chromatography mass spectrometry (LC-MS/MS) and describe how antibody proteomics 
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requires a particularly high stringency in the interpretation of the peptide mass spectra for 
reasons that are intrinsic to antibody gene structure. Finally, we offer specific guidelines 
for the interpretation of antibody peptide mass spectra focusing on correctly distinguishing 
CDR-H3 peptides with shared subsequences. 
EXPERIMENTAL METHODS 
Materials and Reagents 
Concholepas concholepas hemocyanin (CCH), Protein A agarose, Protein G Plus 
agarose, N-hydroxysuccinimide (NHS)-activated agarose, immobilized pepsin resin, and 
Zeba spin columns were acquired from Pierce (Thermo Fisher Scientific, Rockford, IL). 
Incomplete Freund’s Adjuvant (IFA), TRIS hydrochloride (Tris-HCl), ammonium 
bicarbonate (NH4HCO3), 2,2,2-trifluoroethanol (TFE), dithiothrietol (DTT), 
triethylphosphine (TEP),  iodoacetamide (IAM), and iodoethanol (IE) were obtained from 
Sigma-Aldrich (St. Louis, MO). Urea and AG-5Ol-X8 resin were purchased from Bio-Rad 
(Hercules, CA). Microcon 10 kDa MWCO (Microcon-10) centrifugal filter columns from 
Millipore (Bedford, MA) and Hypersep SpinTip C18 columns (C18-SpinTips) from 
Thermo Scientific (Rockford, IL) were used in LC-MS/MS sample preparation along with 
LC-MS Grade water, acetonitrile (ACN), and formic acid from EMD (Billerica, MA). 
Rabbit immunization, V gene sequencing, and preparation of serum antibodies 
Methods for immunization, V gene sequencing, and preparation of antibodies for 
this study were previously described in Wine, et al.7 Briefly, a New Zealand white rabbit 
was immunized with 100 µg CCH protein.  Booster immunization with antigen in IFA was 
administered at days 14 and 28. The animal was sacrificed at day 35. Total RNA was 
isolated from femoral bone marrow cells (BM), peripheral B cells (PBCs), and CD138+ 
bone marrow plasma cells (BM-PCs) and cDNA libraries were generated from poly(A)+ 
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RNA. V gene cDNA was amplified by 5’RACE with primers complementary to rabbit IgG 
CH1 and sequenced using the Roche 454 GS FLX Titanium platform (Roche Diagnostics 
GmbH, Mannheim, Germany). Sequencing data was processed using sequence quality and 
signal filters in the 454 Roche analysis pipeline, followed by identification of conserved 
framework regions and V germline gene identification using the IMGT/HighV-Quest Tool.  
Additional filters were applied to remove truncations (sequence length <70 amino acids, 
misalignment of framework regions FR1 and FR4) and sequences containing stop codons 
or ambiguous reads. In total, >1.5x105 reads were obtained, resulting in 107,672 unique 
full-length, in-frame VH genes. For reference sequence database construction, single read 
sequences were excluded to reduce the impact of sequencing errors (18,593 VH genes ≥2 
reads). 
Serum IgG was purified by protein A agarose affinity chromatography, and F(ab’)2 
fragments generated by digestion with immobilized pepsin. Antigen-specific IgG-derived 
F(ab’)2 was isolated by affinity chromatography against CCH protein coupled to NHS-
activated agarose and eluted in 100mM glycine pH 2.7. Immediately following elution, the 
pH was neutralized with 1M Tris-HCl, pH 8.5. Protein concentrations were measured using 
an ND-1000 spectrophotometer (Nanodrop, DE, USA). 
Alternative cysteine alkylation and trypsin digestion 
Protein samples were concentrated on Microcon-10 columns and split into aliquots 
for alternative cysteine modification. For IAM alkylation, aliquots were resuspended in 
50% (v/v) TFE, 50 mM NH4HCO3 and 2.5 mM DTT, and incubated at 37°C for 60 min. 
Reduced samples were then alkylated with 32 mM IAM at room temperature, in the dark, 
for 60 min. Alkylation was quenched by addition of 7.7 mM DTT. Samples were diluted 
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to 5% TFE and digested with trypsin at a ratio of 1:75 trypsin:protein at 37 °C for 5 hours. 
Digestion was halted by addition of formic acid to 1% (v/v) concentration. 
For IE alkylation, trypsin digestion in the presence of urea was carried out as 
previously described79 with the following modifications:  Samples were resuspended in 8 
M urea, then diluted to a final reaction solution consisting of 2.4 M urea, 200 mM 
NH4HCO3 pH 11.0, 49% (v/v) ACN, 8.5 mM TEP, and 65 mM IE. pH was adjusted to 10 
and samples incubated at 37 °C for 60 min. Samples were concentrated by SpeedVac 
(Eppendorf, NY, USA) and resuspended in 100 mM Tris-HCl, pH 8.5 to reach a final urea 
concentration of 1.6 M prior to trypsin digestion. Trypsin was added at a ratio of 1:75 
trypsin:protein at 37 °C for 5 hours.  The digestion was quenched with 1% formic acid. 
Human raw spectral data and VH sequence database 
All human data used in this study corresponds to the donor HD1 dataset previously 
described in Lavinder, et al.1 In summary, a healthy human subject (HD1) was 
administered the tetanus toxoid/diphtheria toxoid vaccine (Sanofi Pasteur MSD GmbH, 
Leimen, Germany) for booster immunization 7 years after previous booster. VH and VL 
gene sequences from plasmablasts and memory B cells isolated at 7 days and 3 months 
post-boost were determined by Roche 454 sequencing. Sequence data was processed and 
filtered as described for rabbit sequencing. In total, 70,326 VH gene sequences were used 
in construction of the human HD1 reference sequence database. 
IgG was purified by affinity chromatography with Protein G Plus agarose from 
serum samples collected at pre-vaccination (day 0), 7 days, 3 months, and 9 months post-
vaccination, and digested with immobilized pepsin resin to generate F(ab’)2 fragments.  
Antigen-specific F(ab’)2 was isolated by affinity chromatography against vaccine-grade 
tetanus toxoid protein (Statens Serum Institut, Copenhagen, Denmark) coupled to NHS-
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activated agarose and eluted with 20 mM HCl (pH 1.7). Eluted samples were neutralized 
with 1 M NaOH, 10 mM Tris-HCl and desalted on a 2 ml Zeba spin column prior to 
denaturation with 50% TFE, reduction with 10 mM DTT, and alkylation with 32 mM IAM. 
Samples were diluted 10-fold with 50 mM NH4HCO3 and digested with trypsin (1:35 
trypsin:protein) overnight at 37°C. Digestion was quenched with 1% formic acid. 
Sample preparation for LC-MS/MS 
Digested IAM (human, rabbit) and IE (rabbit) samples were concentrated by 
SpeedVac, resuspended in Buffer C (5% ACN, 0.1% formic acid), and loaded and washed 
on C18-SpinTips according to the manufacturer’s protocol. Bound peptides were eluted in 
60% ACN, 0.1% formic acid, concentrated by SpeedVac, resuspended in Buffer C and 
filtered through Microcon-10 columns prior to LC-MS/MS analysis. 
Construction of target and decoy databases 
Sample-specific target protein sequence databases were constructed for SEQUEST 
searches of rabbit and human mass spectral data.  The CCH rabbit database consisted of 
VH and VL gene sequences (≥2 reads), Ensembl rabbit protein-coding sequences 
(OryCun2.0), and common contaminants (from MaxQuant website, 
http://maxquant.org/contaminants.zip).  The human HD1 database included VH and VL 
gene sequences, Ensembl human protein-coding sequences (release 64, longest sequence 
variant/gene), and MaxQuant common contaminants. 
Decoy databases were constructed for rabbit and human analyses to evaluate the 
effects of decoy variants on error modeling of V-gene peptides. Reversed and shuffled 
databases were generated for each database at the protein level. Additionally, conserved-J 
region shuffled decoys were generated by preserving the conserved J-segment sequence 
(which directly follows the CDR-H3) of VH gene sequences. For the remaining V gene 
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sequence, amino acids between arginine and lysine residues were shuffled, with Arg/Lys 
residues fixed to preserve peptide length and precursor mass distributions. 
Computational interpretation of peptide mass spectra 
Spectra were searched against the various protein sequence and decoy databases 
described above using SEQUEST (Proteome Discoverer 1.3, Thermo Scientific).  Fully-
tryptic peptides with up to 2 missed cleavages were considered. Mass tolerance filters of 5 
ppm (MS1) and 0.5 Da (MS2) were applied. Static cysteine modifications of either 
carbamidomethylation (IAM-alkylation, +57.0215 Da) or ethanolyl (IE-alkylation, 
+44.0262 Da) were included based on which modifying reagent was used. Oxidation of 
methionine (+15.9949 Da) was allowed as a dynamic modification. PSMs were filtered 
using Percolator (implemented in Proteome Discoverer) to control false discovery rates 
(FDR) to <1% as determined using a reverse-sequence decoy database.80 All observed 
precursor masses were recalibrated according to the methods of Cox, et al.,81 and the 
average mass deviation (AMD) was calculated for all high-confidence PSMs (Percolator 
FDR <1%) matching the same reference peptide, as the mean difference between the 
observed precursor masses and the expected mass of that reference peptide in units of ppm. 
Due to the high frequency of isobaric peptides with isoleucine-leucine substitutions in V-
gene sequences, we considered all Iso/Leu sequence variants as a single group, and mapped 
the group to all CDR-H3 peptides associated with any of the group members. For other 
isobaric pairings (e.g. Asp/Gly-Gly, Gln/Gly-Ala) and ambiguous identifications where 
MS/MS spectral differences can distinguish between pairings, we considered only the top-
ranked PSM determined by the SEQUEST-Percolator pipeline. 
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Survey of covalent peptide modifications  
In order to confirm the specificity of cysteine modifications and to assess the 
general overall presence of covalent post-translational modifications (PTMs) among 
antibody peptides, raw peptide mass spectra from the rabbit samples were computationally 
searched for the dominant, differentially observed PTMs as follows: Tandem mass spectral 
sets were first reduced in size and complexity through spectral clustering, in which merged 
spectra were represented by a single consensus spectrum. For each sample, spectra were 
initially grouped based on precursor mass so that all the members within a group were 
within 25 ppm of at least 1 other member. Hierarchical clustering was performed on the 
tandem mass spectra of each weight group using a fuzzy cosine similarity metric and 
weighted linkage criteria with a distance cutoff of 0.25. The fuzzy cosine similarity, or 





where Ac is the convolution of spectrum A with a Gaussian 1 Da in width. This serves to 
influence the correlation by both the intensity of each peak pair and the closeness of the 
peaks in m/z. Spectra composing each cluster were then reduced into a single consensus 
spectrum. An average parent ion mass was then assigned to each cluster. 
All pairs of spectral clusters between IAM- and IE-labeled samples were compiled 
with the constraint that the parent ion mass difference between pair members fell within 
±60.5 Da. Similarity measures were calculated for each pair, the sum of which was a 
composite metric for judging spectral correlation. Pairs were then binned in 2D arrays by 
mass offset and composite correlation score. Because clusters had varying numbers of 
members, all cluster pairs were not equal and were therefore weighted by 0.5 plus the log 
of the product of the two membership counts. The sum of these weights gave a single 
 31
summary statistic for each bin, and the data was visualized as a stacked bar graph consisting 
of 121 offset bins of width 0.02 Da that are centered at an integer value. 
Differential analysis of cysteine modifications  
PTM analysis (described above) was used to identify pairs of spectral clusters 
exhibiting an observed parent mass difference of 12.995 +/-0.005 Da (or 25.99 +/-0.005 
Da for two Cys) between IAM- and IE-treated samples. Paired clusters with similar elution 
times and fragmentation patterns were flagged as originating from cysteine-containing 
peptides. The top-ranked SEQUEST peptide identification for each cluster was then 
considered. If the same sequence was identified in both treatments (inherently requiring 
the presence of cysteine to match), the peptide sequence was flagged as a likely correct, or 
“true positive”, identification. If the peptide identification differed between treatment sets 
(precluding the presence of cysteine in the sequence), the corresponding peptide sequences 
were flagged as definitely incorrect, or “false positive”, identifications. 
RESULTS AND DISCUSSION 
The goal of serum antibody proteomics is to systematically identify the distinct 
antibodies present in a serum sample, as assayed through the use of shotgun proteomics 
mass spectrometry.  To achieve this, our approach relies on the integration of two main 
experimental pipelines: 
1. High-throughput sequencing of B lymphocyte cDNAs to generate a database of 
class-switched antibody variable domain sequences in a particular individual. 
2. A protein biochemistry and mass spectrometry-based proteomics pipeline for the 
identification of peptides derived from antigen-specific antibodies. 
A personalized reference sequence database generated by the high-throughput 
sequencing pipeline is used in the interpretation of antibody-derived peptide mass spectra 
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obtained through the proteomics pipeline.  Identified peptides can be mapped back onto 
the antibody sequence database to determine the distribution of specific clonotypes 
comprising the antigen-specific repertoire.  However, the frequency of degenerate peptides 
mapping to multiple clonotypes complicates this analysis. Given that the CDR-H3 is the 
most hypervariable region in immunoglobulins and is overwhelmingly responsible for 
antigen specificity, as well as being the primary determinant of clonality, this problem can 
be largely simplified to that of the quantitation and sequence determination of CDR-H3 
peptides. The remaining sequence of each antibody can then be retrieved from the V gene 
reference database. 
For this study, we largely focused on analysis of serum samples from a New 
Zealand white rabbit (Oryctolagus cuniculus) immunized with Concholepas concholepas 
hemocyanin (CCH). Sequencing data for this rabbit was previously described,7 and is 
summarized in Materials and Methods.  We focus here only on the VH sequences; while 
the partner VL chain contributes to antibody stability and binding characteristics, native 
VH-VL pairing information cannot be determined by proteomic analysis, but can be 
derived by other methods once VH chains are known.6,7 
From this rabbit we prepared antigen-specific F(ab’)2 fragments, proteolytically 
digested them with trypsin and analyzed the resulting peptides by quantitative shotgun 
proteomics, employing nanoflow LC-MS/MS (see Materials and Methods). A 
conventional analysis of the peptide mass spectra would involve comparing the spectra 
against the rabbit’s VH gene database in order to identify those antibodies actually present 
in the serum. However, as we next discuss, the conventional proteomics database search 
process is insufficient for the analysis of antibody peptide mass spectra due to intrinsic 
properties of the antibody sequences. 
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The mass spectrometry proteomics data have been deposited to the 
ProteomeXchange Consortium82 via the PRIDE partner repository, with dataset identifiers 
PXD000916 (Rabbit) and PXD000917 (Human). 
Limitations of standard peptide-spectrum assignments and decoy-based error 
modeling 
While the general process of identifying the best peptide-spectrum match (PSM) is 
well established for conventional datasets searched against normal proteomic sequence 
databases,83,84 V-gene databases contain unique sequence characteristics which pose 
challenges to this standard method of data interpretation. 
Under the standard target-decoy approach, candidate peptides within a specified 
mass range of the parent ion are initially scored based on cross-correlation to the observed 
fragmentation spectrum (XCorr), subjected to additional quality filters, and ultimately 
assigned confidence scores by reference to the score distributions of decoy sequences. For 
a conventional proteome, the occurrence of multiple peptides sharing partial sequence 
identity and mass is extremely rare, as can be seen for proteins sampled from the human 
proteome (Figure 2.2a). Thus, while multiple theoretical peptides may fall close in mass to 
a given precursor ion, the correct peptide sequence will almost always match the MS2 
spectrum with a significantly higher score than competing, incorrect peptides. This is 
reflected by the positive correlation between XCorr and the normalized difference in XCorr 
between the top two PSMs of a given spectrum (ΔCN) (Figure 2.3a). 
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Figure 2.2:  Theoretical extent of peptide-spectral match ambiguity for human proteome 
and antibody peptides. 
In contrast to the proteome in general, antibody peptide sequences resemble each other in 
both mass and expected fragmentation patterns. The peptide sequence search space is thus 
strongly dependent on mass accuracy, as seen by plotting the extent of theoretical peptide-
spectral match ambiguity, for (A) human proteome peptide sequences, (B) rabbit CCH 
antibody VH peptides , and  (C) human tetanus toxoid antibody VH peptides. Reducing 
precursor mass tolerance thus more strongly affects the potential for false identifications 
in VH peptides than for a typical proteome. Here, an in silico digest of the rabbit CCH VH 
antibody sequences generated 505,790 unique peptide sequences (constrained to fully 
tryptic peptides of ≥ 8 amino acids, ≤ 6000 Da theoretical mass, and ≤ 2 missed cleavages). 
Each peptide sequence contributes to a y-axis bin defined by the self-inclusive count of all 
theoretical peptides within a specified mass tolerance (x-axis) and sharing at least 60% 
predicted fragmentation ion similarity. For comparison, the human proteome (A) and 
human TT VH (C) sequence databases were processed likewise and subsampled to include 
the same number of peptide sequences as (B). The inter-sequence similarity evident in the 
antibody sets is negligible in this size-matched human proteome control. 
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Figure 2.3: Antibody VH spectra often show multiple high-scoring PSMs, problematic for 
standard target-decoy FDR methods. 
Confidently-identified spectra from most proteomics samples generally score well against 
only one database sequence. The interspersal of conserved (framework) and variable 
regions in antibody F(ab')2 sequences often leads to multiple high-scoring PSMs for a 
single IgG-VH peptide spectrum. Plotting the primary PSM score (XCorr) vs. the 
normalized difference in XCorr scores between the two top-scoring matches (ΔCN) from 
proteomic analysis of (A) human HeLa cell lysate compared to (B) rabbit and (C) human 
IgG-VH peptide spectra reveals a substantial proportion of high XCorr/low ΔCN PSMs 
(denoted by black boxes) in the IgG-VH datasets. Standard false discovery rate (FDR) 
calculations fail for these PSMs, as illustrated by high (blue), medium (green), and low 
(red) Percolator confidence scores: many high XCorr/low ΔCN PSMs are erroneously 
assigned high confidence in spite of high-scoring second hits implicit in the low ΔCN 
values. Filtering out low ΔCN PSMs inadvertently removes many true hits. Comparison of 
PSM XCorr distributions between target (blue) and decoy (red) databases reveals that 
standard decoys do not adequately model the non-random structure of IgG-VH peptides 
[(D) human proteome, (E) rabbit IgG-VH, (F) human IgG-VH]. This is attributable to high-
scoring, incorrect matches to IgG framework region-derived sequences. By constructing 
an alternate decoy database that preserved J-region framework regions (“Conserved-J 
Decoy”), ambiguity of CDR-H3,J peptide assignment can be modeled (green). These 
peptides account for the majority of high-XCorr PSMs in rabbit (E), while additional 
framework-derived peptides add to the complexity of the human IG-VH sample (F, inset). 
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For the case of immunoglobulin variable genes, however, large numbers of peptide 
sequences overlap in both mass and partial sequence identity (as plotted for our VH 
datasets in Figure 2.2b,c), yielding sets of highly-similar theoretical MS2 spectra. This 
confounds proteomics analysis and often results in, for a single spectrum, multiple 
ambiguous peptide-spectral matches sharing similarly high PSM correlation scores 
(observed as high-XCorr/low-ΔCN, i.e. high scoring-second rank hits) (Figure 2.3b,c). In 
some cases, incorrect sequences out-score the correct PSMs. Even when applying an 
extremely strict mass accuracy filter— requiring a peptide mass to fall within 5 ppm of the 
observed precursor ion mass to be considered—false identifications are still prevalent. 
V-gene sequence similarity also effects decoy-based error-modeling. Standard 
errors in PSM assignment normally arise from poor quality spectra, which contain 
significant noise and/or additional peaks due to unaccounted for contaminating peptide 
fragments following ion isolation. In order to assign PSM confidence and calculate a false 
identification rate, a decoy reference database of either reversed or shuffled protein 
sequences is generally used to model this standard error, allowing for confidence-filtering 
based on discernible differences in the distribution of true and false positive PSMs (Figure 
2.3d).84,85 Software programs such as Percolator80 analyze multiple parameters of target 
and decoy results (including XCorr, ΔCN, and others) in order to determine a set of high-
confidence PSMs at a given FDR (Figures 2.3a-c). For the case of Ig V genes, reversing or 
shuffling sequences did not replicate the high incidence of high scoring-second rank hits 
observed in the forward search, demonstrating that a standard decoy database fails to model 
this aspect of IgG sequences (Figures 2.3e,f). 
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Immunoglobulin PSM ambiguity arises from Ig peptides containing highly 
immutable framework regions 
To further investigate this trend, we focused on the partial sequence identity of 
CDR-H3-containing peptides. Most such peptides also contained the entirety of the J-
region subsequence in both the rabbit and human samples, generally a series of 12 or more 
residues sharing exceptional self-similarity within each species. Hence, peptides 
containing the J-region shared a significant fraction of identical peaks within their 
fragmentation spectra, in addition to peaks contributed by the variable CDR-H3 sequence 
(Figure 2.4). 
 
Figure 2.4: CDR-H3 sequence differences between high-confidence PSMs are not 
reflected in the MS/MS spectrum. 
High-scoring PSMs for antibody CDR-H3 peptide mass spectra are dominated by matches 
to peptides sharing identical C-terminal J region FR4 framework sequences. This is 
illustrated by two top-scoring peptide sequences mapped to a single observed rabbit 
spectrum, with shared (orange) and unique in silico predicted MS2 fragmentation peaks 
associated with APYGDGDPYNLWGPGTLVTVSSGQPK (blue) and 
DAGTSGYHFNLWGPGTLVTVSSGQPK (green).  Both sequences exhibit PSMs with 
XCorr > 4.7 with a normalized difference in XCorr scores (ΔCN) of 0.006. A similar trend 
accounts for a large proportion of the high-scoring matches in Figs. 2.3b and d. 
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In order to assess the magnitude of this effect on the resulting PSM scores, we 
generated sample-specific shuffled decoy databases in which the J-region residues were 
explicitly preserved (“Conserved-J Decoy”). Importantly, the Conserved-J Decoy database 
reproduced the incidence of high scoring-second rank hits observed in the J-region peptides 
and evident in the VH forward peptide database (Figure 2.3e,f[inset]). A significant portion 
of high scoring-second rank hits can therefore be attributed to CDR-H3-containing peptides 
partially matching other CDR-H3-containing peptides by their conserved J region 
sequences. More generally, Ig peptides containing an antibody framework region at one 
terminus are subject to this kind of ambiguous PSM assignment. Consequently, standard 
decoy-based error modeling significantly underestimates false identifications for this class 
of peptides. 
Construction of a high-confidence set of rabbit VH identifications 
In order to determine the prevalence of incorrect identifications and find 
characteristics on which to discriminate between true and false matches, we employed 
differential labeling of cysteine residues to create a set of higher confidence identifications 
consistent with the cysteine labeling data and to flag a subset of definitively incorrect 
identifications as high-scoring false positives (Figure 2.5a). Rabbit F(ab’)2 fragments were 
divided into two aliquots. One aliquot was alkylated with iodoacetamide (IAM), while the 
second was alkylated with iodoethanol (IE). This created equivalent samples with the 
exception of a 13 Da mass difference between modified cysteine residues in the two 
samples. 
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Figure 2.5: Differential cysteine modification and naïve identification of common PTMs. 
A limited set of higher-confidence identifications can be created using differential covalent 
modification to flag cysteine-containing peptides. (A) Comparison of rabbit CCH spectra 
from samples treated with iodoacetamide (Cys +57Da) vs. iodoethanol (Cys +44Da) results 
in a 13Da mass difference per cysteine.  PSMs for paired spectra exhibiting a mass shift 
but no cysteine residues in the corresponding matched sequences can be flagged as false 
identifications. (B) Comparison of precursor mass offsets between differentially labeled 
rabbit CCH samples confirms alkylation and oxidation account for the most abundant 
modifications. 
Following LC-MS/MS analysis, datasets corresponding to IAM- and IE-treated 
samples were compared to identify parent ion pairs across the two datasets exhibiting the 
signature 13 Da mass difference, similar chromatographic elution times, and correlated 
MS2 fragmentation spectra. Qualifying ion pairs were considered cysteine-containing; 
upon peptide-spectrum sequence assignment, ion pairs with identical sequences containing 
cysteine residues and displaying the 13 Da difference in the two aliquots were flagged as 
more likely to be correct, and considered for these purposes to be “true positive” 
identifications. In contrast, those spectra shifted by 13 Da but lacking a cysteine residue in 
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their assigned sequences were considered definitely incorrect, or “false positive”. By 
flagging peptides in this manner, we defined a set of 53 “true positive” and 40 “false 
positive” peptide identifications comprising 11,077 and 425 PSMs, respectively. This set 
was used both to diagnose PSM assignment error and to define filtering criteria appropriate 
for more general application across all PSMs, not just those containing cysteine residues. 
To further assess these samples, we examined the frequency of all potential 
precursor ion mass offsets between the differentially treated samples so as to survey the 
most common covalent modifications, thus confirming the cysteine modifications and 
testing for other potential modifications (Figure 2.5b). Besides modified cysteine, only one 
other prevalent modification was found, occurring in both samples at a mass offset of 15.99 
Da and consistent with oxidation. Detailed manual analysis of fragmentation spectra 
confirmed oxidized methionine as the main contributor to this offset peak. 
A stringent average mass accuracy filter successfully removes false identifications 
Using the high confidence true and false identification sets, we searched for mass 
spectral properties that distinguished these cases. We observed a robust difference in mass 
accuracy distributions (defined as the difference between observed precursor mass and 
expected peptide mass, in units of parts per million (ppm)), with the “true positive” PSMs 
centered around 0.127 ppm with a standard deviation of 0.637 ppm (following mass 
recalibration), while “false positive” PSMs were more evenly distributed throughout the 
mass range. This signal, while clear, was not suitable for direct use as a mass accuracy 
filter at the level of PSMs, since many individual “true positive” PSMs still deviated from 
expected mass by several ppm. Application` of a strict mass accuracy filter to remove false 
PSMs would therefore inevitably remove many true PSMs as well (Figure 2.6a). 
 41
Figure 2.6 A large average mass deviation indicates peptide misidentification. 
Correctly matched PSMs exhibit a systematically smaller average mass deviation (AMD) 
compared to incorrect identifications.  (A)  Plotting the difference in precursor ion mass 
from expected peptide mass (Precursor Mass Accuracy) vs. XCorr scores of individual 
rabbit CCH PSMs reveals overlapping mass accuracy distributions for PSMs matched to 
the same peptide sequence for correct (blue) and incorrect (red) identifications. While 
individual incorrect PSMs may achieve higher XCorr scores than correct matches, the 
average precursor mass accuracy across all PSMs for a given peptide (AMD) discriminates 
well between correct and incorrect identifications. (B) For the set of high-confidence rabbit 
CCH PSMs derived from cysteine-labeling, true identifications exhibit low AMD scores 
while false identifications are more uniformly distributed. Thus, filtering by AMD strongly 
controls misidentifications. Here, controlling AMD to within 1.5 ppm provides 100% 
recall of true identifications and increases precision from near 50% (background rate) to 
79%. Requiring AMD < 1 ppm further increases precision to 87% with no loss of recall. 
However, the average mass deviation (AMD) of a peptide identification, calculated 
as the average mass accuracy of all high-confidence PSMs associated with a given peptide, 
showed an extremely narrow distribution for the “true positive” set (mean 0.141 ppm, stdev 
0.238 ppm). In contrast, the “false positive” set exhibited a roughly uniform AMD 
distribution across the mass range. Consequently, filtering hits by applying a strict AMD 
filter was feasible without substantial loss of true identifications. Requiring AMD < 1.5 
ppm in this dataset improved the precision from a prior rate of approximately 50% to 79%, 
with no loss of true identifications. Applying an even stricter AMD threshold of 1 ppm 
further improved the precision to 87%, again with no loss of true identifications (Figure 
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2.6b). High mass accuracy LC-MS/MS is therefore sufficient to identify antibody CDR-
H3 peptides from serum at relatively high precision when combined with a stringent AMD 
filter beyond the conventional proteomics analytical pipeline. 
CONCLUSIONS 
Proteomic analysis of serum immunoglobulins has only recently become feasible 
with the ability to generate appropriate mass spectrometry reference databases via next-
generation sequencing of individual B cell antibody repertoires. Even with an appropriate 
custom database in hand, however, antibody sequences still present significant challenges 
for mass spectral interpretation due to the frequency of interspersed variable and conserved 
amino acid sequences within the same peptides. We’ve shown how these sequence 
properties lead to certain systematic trends in the fragmentation spectra of antibody-derived 
peptides, which introduce additional errors in peptide-spectrum correlation scoring not 
accounted for by standard decoy-based error modeling. The observation of similar 
sequence properties in rabbit and human datasets indicates that these are intrinsic features 
of immunoglobulin primary structure which should be accounted for in any proteomic 
analysis of antibody repertoire, regardless of species. To this end, we have demonstrated a 
strategy to reduce false discovery and improve the accuracy of antibody identification by 
shotgun proteomics through the use of high mass accuracy LC-MS/MS and high stringency 
filters applied to groups of peptide-spectral matches, rather than individual PSMs.   
These findings highlight the importance of evaluating methods of data analysis 
when applied to non-standard datasets. While we specifically addressed complications 
encountered in the analysis of antibodies, we would expect similar trends for any protein 
samples where many close variant sequences might be present, such as in samples assaying 
human genetic variants or large protein families with related sequences. 
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Chapter 3: UVnovo: A De Novo Sequencing Algorithm Using Single 
Series of Fragment Ions via Chromophore Tagging and 351 nm 
Ultraviolet Photodissociation Mass Spectrometry 
De novo peptide sequencing by mass spectrometry represents an important strategy 
for characterizing novel peptides and proteins, in which a peptide’s amino acid sequence 
is inferred directly from the precursor peptide mass and tandem mass spectrum (MS/MS 
or MS3) fragment ions, without comparison to a reference proteome.* This method is ideal 
for organisms or samples lacking a complete or well-annotated reference sequence set. One 
of the major barriers to de novo spectral interpretation arises from confusion of N- and C-
terminal ion series due to the symmetry between b and y ion pairs created by collisional 
activation methods (or c, z ions for electron-based activation methods). This is known as 
the ‘antisymmetric path problem’ and leads to inverted amino acid subsequences within a 
de novo reconstruction. Here, we combine several key strategies for de novo peptide 
sequencing into a single high-throughput pipeline: high efficiency carbamylation blocks 
lysine side chains, and subsequent tryptic digestion and N-terminal peptide derivatization 
with the ultraviolet chromophore AMCA yields peptides susceptible to 351 nm ultraviolet 
photodissociation (UVPD). UVPD-MS/MS of the AMCA-modified peptides then 
predominantly produces y ions in the MS/MS spectra, specifically addressing the 
antisymmetric path problem. Finally, the program UVnovo applies a random forest 
algorithm to automatically learn from and then interpret UVPD mass spectra, passing 
results to a hidden Markov model for de novo sequence prediction and scoring. We show 
this combined strategy provides high performance de novo peptide sequencing, enabling 
the de novo sequencing of thousands of peptides from an E. coli lysate at high confidence. 
                                                 
* Chapter 3 has been previously published in: Robotham, S. A.; Horton, A. P.; Cannon, J. R.; Cotham, V. 
C.; Marcotte, E. M.; Brodbelt, J. S. Anal. Chem. 2016, 88 (7), 3990–3997. 
S.A.R. and A.P.H. contributed equally. 
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INTRODUCTION 
The breadth of proteomic studies has never been greater, as a growing trend in 
proteomics research pushes mass spectrometry experiments beyond the study of model 
organisms, proteotypic peptides, and common post-translational modifications. This 
strains the limits of traditional spectral interpretation using sequence databases, and it has 
driven development of more flexible search methods and proteogenomic pipelines. De 
novo peptide and protein sequencing is one potential strategy for characterizing novel 
peptides.86 Rather than comparing a peptide spectrum to theoretical candidate spectra from 
a reference protein sequence database, de novo analysis directly infers a peptide sequence 
from the precursor peptide mass and tandem mass spectrum (MS/MS or MS3) fragment 
ions.87 This method is ideal for organisms or samples lacking a complete or well-annotated 
reference sequence set. In the event that gene sequences are available, de novo approaches 
are well suited for interpreting unidentified spectra and discovering unknown splice 
variants, intergenic peptides, sequence polymorphisms, and other novel peptides. 
Given an ideal MS/MS spectrum, de novo peptide sequence assignment is a trivial 
exercise. Such a spectrum would exhibit a complete series of ions, all of a single fragment 
type (N-terminal a/b/c or C-terminal x/y/z ions) and known charge state, that span an entire 
precursor peptide. The sequence could then be read directly from the spectrum by matching 
the mass difference between each consecutive ion pair to its corresponding amino acid. 
Technological developments, notably high-resolution MS/MS acquisition and concurrent 
collection of complementary fragmentation spectra (e.g. paired collision-induced 
dissociation (CID)/Electron transfer dissociation (ETD) mass spectra), have greatly 
improved the potential of de novo peptide sequencing, but spectra still suffer from 
incomplete peptide fragmentation, complex fragmentation patterns and neutral losses, and 
uninterpretable noise. CID,88,89 HCD,90 ETD,91,92 and dual fragmentation (EThcD, 
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ETciD),93 have all been applied for de novo sequencing. Infrared multiphoton dissociation 
(IRMPD) and ultraviolet photodissociation (UVPD)94–97 are also emerging as viable 
alternatives for tandem mass spectrometry of peptides. 
One of the major barriers to de novo spectral interpretation arises from confusion 
of N- and C-terminal ion series due to the symmetry between b and y ion pairs created by 
collisional activation methods (or c, z ions for electron-based activation methods). This is 
known as the ‘antisymmetric path problem’ and leads to inverted amino acid subsequences 
within a de novo reconstruction.98 A related difficulty arises when fragment ions with 
similar m/z values cannot be independently resolved.99 Biased peptide backbone 
fragmentation, the most serious problem, leads to spectral regions without fragment ion 
evidence and precludes definition of a complete amino acid sequence. These issues have 
made it unrealistic in practice to assign full and accurate peptide sequences in an automated 
de novo fashion. Therefore, database searches still greatly outperform de novo in any 
complex bottom-up shotgun proteomics experiment for which representative sequence data 
is available. Many modern de novo algorithms compensate by reporting tens or hundreds 
of putative sequences for a single peptide spectrum or only partial peptide sequences 
containing gaps where amino acids cannot be derived.100,101 The results are most useful 
after manual curation or homology-based database comparisons, where such hybrid 
sequence tag-based homology searching combines the flexibility of de novo sequencing 
with the identification power provided through database comparison. 
Among the many de novo programs available today, a few of the more popular 
established and emerging options include PEAKS, PepNovo, NovoHMM, pNovo, 
DirecTag and Novor for bottom-up proteomics and Twister for top-down analysis.99,102–107 
Most such tools use statistical models of peptide fragmentation for spectral interpretation 
prior to sequence generation, or for scoring candidate de novo sequences constructed from 
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simple initial assumptions and rules. These fragmentation models are rooted in the idea of 
the offset frequency function (OFF), introduced by Dančík et al. in 1999.108 Fundamentally, 
the OFF treats fragmentation as a stochastic process whereby specific ions (ex. b+, y+-NH3) 
have a certain chance for being observed from each peptide residue position. These models 
are highly dependent on the type of spectra used during construction, limiting the 
application of existing software for new spectral paradigms. 
In parallel to the continued development of de novo interpretation software, 
considerable effort has focused on creating “ideal” spectra for de novo sequencing through 
novel sample preparation and instrumentation methods.87 Most of these methods have been 
implemented to overcome the antisymmetric path problem or more generally, the issue of 
discerning product ion type. Differential labeling between two samples, via isotopic or 
chemical modification of peptide N- or C-termini, is applied to evoke a mass difference 
between product ions pairs and allows MS2 ion type annotation.109,110 Alternatively, 
spectral simplification through chemical derivatization and charge sequestration can either 
enhance or eliminate a particular fragment ion series. In particular, peptide termini may be 
modified to increase the relative intensity of either the N- or C-terminal ion series.111,112 
Changing the basicity or charge of a peptide terminus influences the charge distribution 
along an ionized peptide and, consequently, produces a more prominent series of 
fragmentation ions from the end where charge is concentrated. 
We recently demonstrated marked spectral simplification through a combination of 
chromophore derivatization and UVPD-MS.113,114 The simplification mechanism, 
fundamentally different from those described above, destroys rather than neutralizes 
redundant fragment ions. By attaching the chromophore 7-amino-4-methylcoumarin 3-
acetic acid (AMCA) to a peptide N-terminus, the peptide becomes susceptible to 351 nm 
photoactivation. The selectivity of 351 nm UVPD ensures that only AMCA-derivatized 
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peptides undergo photodissociation, and successive laser pulses effectively eliminate N-
terminal chromophore-containing ions. C-terminal product ions remain unaffected by the 
UVPD, and the process yields a clean series of y ions uniformly distributed along the entire 
peptide length. 
In this paper, we combine three key strategies for de novo peptide sequencing into 
a single high-throughput pipeline: (i) covalent modification of peptides and (ii) 351 nm 
UVPD fragmentation to favor N-terminal fragment ions with (iii) a dedicated software 
platform, UVnovo, to interpret these data. We introduce an improved strategy for selective 
peptide N-terminal AMCA derivatization. This is accomplished through highly efficient 
carbamylation of lysine side-chain amines115 prior to tryptic digestion and AMCA labeling. 
LC-UVPD-MS/MS of the AMCA-modified peptides then predominantly produces y ions 
in the MS/MS spectra, specifically addressing the antisymmetric path problem. Finally, the 
program UVnovo applies a random forest (RF) algorithm116 to automatically learn from 
and then interpret UVPD spectra, passing results to a hidden Markov model (HMM) for de 
novo sequence prediction and scoring. We show this combined strategy provides high 
performance de novo peptide sequencing. 
MATERIALS AND METHODS 
Materials 
Trypsin Gold, Mass Spectrometry Grade was purchased from Promega (Madison, 
WI, USA). LC-MS grade acetonitrile and water were purchased from EMD Millipore 
(Darmstadt, Germany). Phosphate buffered saline (PBS) and dimethyl sulfoxide (DMSO) 
were purchased from Thermo Fisher Scientific Inc. (San Jose, CA, USA). 
Sulfosuccinimydyl-7-amino-4-methyl-coumarin-3-acetic acid (Sulfo-NHS-AMCA) was 
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purchased from Pierce Biotechnology (Rockford, IL, USA). E. coli lysate was graciously 
donated by Dr. M. Stephen Trent’s research group at the University of Texas at Austin. 
Modification of E. coli lysate 
Figure 3.1 shows the process for N-terminal AMCA peptide derivatization. 50 μg 
of E. coli lysate in 100 μL of 50 mM sodium carbonate and 8 M urea was heated at 80 °C 
for 4 hours to carbamylate lysine side chains (ε-amines) and N-termini primary amines, 
blocking subsequent reaction with AMCA. Urea was removed through PBS buffer 
exchange, and proteins were then digested using trypsin at 37 °C overnight. After digestion, 
25 µL of 20 mM sulfo-NHS-AMCA in DMSO was added to approximately 270 µL of the 
digest to label the peptides’ primary N-terminal amines, and the solution was kept in the 
dark overnight at room temperature. Samples were cleaned using a C18 SPE cartridge to 
facilitate removal of unreacted AMCA, evaporated to dryness, and resuspended for LC-
MS/MS (98% water/2% acetonitrile with 0.1% formic acid). 
Figure 3.1: Workflow for peptide N-terminal AMCA derivatization. 
(a) Carbamylation blocks primary amines (Lys and protein N-terminus) from subsequent 
AMCA derivatization and prevents lysine from tryptic cleavage. After digestion, AMCA 
labeling occurs at the new peptide N-terminal amines. (b) The carbamylation reaction. 
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LC-MS/MS analysis of E. coli lysate 
All mass spectra were acquired using a Thermo Scientific Velos Pro dual linear ion 
trap mass spectrometer (Thermo Scientific; San Jose, CA) modified for UVPD by addition 
of a Coherent 351 nm excimer laser (Coherent; Santa Clara, CA, USA) to allow 351 nm 
UV excitation of ions present in the ion trap.117 The laser was set to 3 mJ per pulse at 500 
Hz, with 15 pulses per scan. Peptides were separated by reverse phase chromatography and 
eluted into the mass spectrometer using a Dionex NSLC 3000 nanoLC system (Thermo 
Scientific; Waltham, MA, USA). We used a 15 cm capillary column (75 µm ID) packed 
with 3.5 µm particles (C18 stationary phase) with a pore size of 140 Å, loading 5 µg of 
peptide mixture (via 1 µL injection). Sample elution followed a 360 minute gradient 
starting at 3% B and increasing to 50% B with a flow rate of 300 nL/min; solvent A was 
water with 0.1 % formic acid (v/v), and solvent B was acetonitrile with 0.1% formic acid 
(v/v). 
SEQUEST 
In order to obtain a list of high confidence peptide spectral matches, raw spectra 
were analyzed using the SEQUEST and Percolator nodes of Proteome Discoverer v. 1.4 
(Thermo Fisher Scientific, San Jose, CA). AMCA was required as a fixed N-terminal 
modification, and optional oxidized methionine in any position was allowed. The precursor 
mass tolerance was set at ±1.6 Da due to the low resolution of ion trap spectra. Because 
trypsin does not cleave at carbamylated lysines, SEQUEST protease specificity was set to 
trypsin(R) and included the proline rule. We considered only y ion fragments for the UVPD 
data sets, searching spectra against the UniProt E. coli strain K12 reference proteome. 
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UVnovo de novo sequencing 
We implemented UVnovo, a de novo sequencing program for analysis of UVPD 
spectra, in the MATLAB programming language. All top-ranked high confidence 
SEQUEST peptide spectrum matches (PSMs) from charge 2+ precursor ions were used to 
train and validate UVnovo using three-fold cross validation as follows: 
Spectral partitioning and preprocessing 
Spectra were randomly partitioned into three sets. All spectra from a given peptide, 
collapsing PTM variants, were allocated to the same set, preventing their use for both 
training and validation. During each of the three cross-validation rounds, a different 
partition was treated as an ‘unknown’ test set, and the ‘known’ spectra in the remaining 
two partitions were used for model training. We repeated this three times, withholding a 
different test partition each time, to evaluate the performance of UVnovo against the high 
confidence SEQUEST PSMs. 
Thermo *.raw files were converted to the mzXML format using MSConvert with 
peak picking, and peaks with an intensity < 5 were removed. Through an unexplained 
artifact of UVPD spectral generation, all fragment ions in the MS2 spectra from all 
precursors less than m/z 817.2 were systematically shifted up 0.16 m/z by the instrument, 
whereas peaks of the remaining spectra displayed no such systematic mass error. This was 
corrected in preprocessing by subtracting 0.16 m/z from all peaks of the affected spectra. 
Additionally, because our goal was to evaluate the potential of UVPD-MS/MS for 
automated de novo peptide sequencing, we chose to marginalize the effect of incorrect 
precursor mass on de novo sequence assignment. We set the precursor mass for each 
spectrum to the integer mass nearest its respective SEQUEST PSM. Thus, our results 
should be understood as being contingent on an accurate definition of precursor mass, to 
the nearest 1 Dalton, well within the capacity of modern high-resolution instruments. 
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UVnovo Overview 
Figure 3.2 presents the overall software workflow. Following data import and 
preprocessing, spectral interpretation follows four main steps: 
1. Transform each MS/MS spectrum into a spectral representation of peptide cleavage 
site probability at each possible mass position. This applies a random forest model 
for peptide fragmentation pattern deconvolution. 
2. Refine the backbone cleavage site predictions using a hidden Markov model. 
3. Identify amino acid sequences that best fit the predictions. 
4. Score and rank the de novo sequence reconstructions. 
 
Figure 3.2: UVnovo workflow for de novo sequencing. 
Spectra are divided into training and test sets. A random forest, trained on known spectra, 
transforms an unknown spectrum into a simplified representation of peptide cleavage site 
probabilities. At each position in this ‘simplified spectrum’, a hidden Markov model 
(HMM) refines the probability, also incorporating amino acid frequencies and requiring 
valid mass transitions. The best valid path through the HMM yields the de novo sequence 




Spectral interpretation using machine learning with random forests 
Terms and notation 
For the purpose of simplicity, all subsequent references to peptide and fragment 
mass will be understood as the nominal mass, or integer count of protons and neutrons, 
composing the species under consideration. This reframing simplifies computational 
treatment as well, and we divide real and observed spectral masses by a mass defect 
normalization factor, 1.000468, and round to the nearest integer (e.g. as for Kendrick mass 
calculations).118,119 We retain the highest intensity peak in the case of coincident peaks 
during spectrum normalization. 
We define bare peptide mass  as the total mass of amino acids composing a 
peptide, without the water (18 Da) that is also present in the precursor ion. Each interior 
position is referred to by its prefix (N-terminal) or suffix (C-terminal) mass,  and 
 respectively, and 	 	 . An interior position  represents a 
fragmentation site when the sum of amino acid masses preceding that position equal . 
In other words, the mass of each N-terminal amino acid subseries is a fragmentation site. 
Therefore, 	1 denotes a b ion and 	19 a y ion. 
Fragmentation pattern deconvolution 
Similar to charge deconvolution, where a predictable series of distinct peaks can be 
mapped to single mass, fragmentation pattern deconvolution combines the evidence from 
multiple related peaks into support for a single base peak. For example, the presence of 
associated b, y, and y-H2O ion peaks is strongly indicative of a specific fragmentation site 
along a peptide’s backbone. The deconvolution process simplifies the original spectrum 
and assigns a probability to each mass  that it corresponds to a true precursor peptide 
backbone fragmentation site (the nominal mass of the N-terminal amino acid series 
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preceding that fragmentation site). Such interpretation of fragmentation ion patterns has 
long been the domain of descriptive count-based statistical models,108 but it can likewise 
be approached from a machine learning perspective.106 We introduce here the application 
of random forests to transform MS/MS spectra into predictions of peptide fragmentation 
sites. 
Random forests 
Random forest (RF) classifiers are an ensemble machine learning method that has 
been successfully applied across a wide range of fields.116 This includes in proteomics 
where Degroeve and Martens used RF in their tool MS2PIP to predict MS/MS peak 
intensities given a peptide sequence.120 An ensemble, in machine learning, aggregates the 
results from many individual predictive models into a single output prediction. In 
particular, a random forest ensemble grows a ‘forest’ of independent decision trees. 
Individual trees are simple classifiers often prone to over-fitting, a problem that must be 
carefully guarded against. When combined into a RF or related ensemble, however, they 
turn into very powerful models. 
Decision trees, and therefore RF, can handle an arbitrary number of feature (or 
predictor) variables, either continuous or categorical. Each tree is fit on a random 
resampling with replacement (bootstrapping) from a training data set, using a random 
subset of the predictors at each node in the tree. Enforcing randomness in the construction 
of the individual trees ensures that the trees are uncorrelated, and this reduces the problem 
of over-fitting for the final random forest ensemble. When applied to an unknown 
observation, each tree in the RF returns a binary value, 0 or 1, of class membership. The 
mode of these is taken as the RF prediction and the mean can be treated as a probability of 
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class membership. However, these probability estimates tend toward the extreme, 0 and 1, 
and must be treated cautiously.121,122 
Training random forests to decipher MS/MS fragmentation patterns 
We used the MATLAB implementation of random forests to create an ensemble of 
400 decision trees. A supervised-learning algorithm, RF requires both positive and negative 
training examples (observations), each comprising a potentially large set of feature 
variables (a predictor vector) particular to that observation. Examples are labeled with their 
respective class during RF construction. Here, the positive examples included, for every 
spectrum in the training data, a predictor vector for each fragmentation site. An equal 
number of negative examples were likewise created after applying random shifts (-50 to 
+50 Da) to the true fragmentation sites. 
An observation, representing a specific spectrum and mass position , was 
described by its predictor vector. This feature set primarily included MS/MS peak scores 
for all peak bins (width 1 m/z) spanning the ±50 m/z windows around both  and the 
reciprocal C-terminal position at 	 	–	 . Doubly charged ions were also 
included, adjusting the window locations and widths accordingly. Each of the resulting 404 
features took a normalized peak score rather than a raw intensity, calculated as follows: 
Peak intensities were ranked from highest to lowest in a spectrum, and the rank was divided 
by the bare peptide mass . Local fluctuation in peak intensity was reduced by subtracting 
the minimum rank within a sliding window of ±50 Da. 
Additionally, each predictor vector contained three derived predictors: the 
fractional position within the peptide ( ⁄ ), and the mass positions relative to the N- 
and C-termini discretized into 100 Da regions ( 100⁄  and 100⁄ ). The final 
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two indicated which 100 Da regions the fragment site falls into from the N and C-terminal 
directions. This gave a total of 407 predictor variables at each fragmentation site. 
Random forests can return importance measures of training features as a side effect 
of their construction,116 and we used this to perform feature selection, successively 
identifying and retaining a subset of the most useful predictors through four consecutive 
RF training stages. This iterative RF creation and feature selection reduced the original set 
of 407 predictors down to the 30 most important for  classification. These 30 features 
directed construction of the final RF model. 
By including as features each integer mass offset within ±50 Da of  and , 
this set of predictors indirectly included all of the common fragment ion types a, b, c, x, y, 
and z. We let the machine learning process determine which of these if any should be used 
for the final RF. Additionally, the training automatically identified and utilized interactions 
between predictors. This obviated the need for human oversight and explicit model 
definition seen in most other de novo sequencing packages. 
RF interpretation of unknown spectra 
RF, trained as above, could then be used to interpret unknown spectra. We created 
predictor vectors spanning all potential fragmentation sites  along a spectrum, as 
described above, but only included the 30 features relevant to the RF. The RF converted 
each vector into a probability that its associated  represented a true fragmentation site. 
Therefore, from an unknown spectrum, the RF generates a new ‘spectrum’ of peak 
mass versus fragmentation site probability. This deconvolution process effectively reduces 
a raw spectrum – its various ion peaks, spectral artifacts, noise, and intensity 
inconsistencies – into a much cleaner representation of peptide composition. 
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HMM for refinement of fragmentation site predictions 
We implemented a hidden Markov model (HMM) to refine the RF predictions and 
re-compute probabilities across all potential peptide fragmentation sites.123 Each node, or 
state, in the HMM is a possible fragmentation site and is described by both its position 
along the spectrum ( ) and its position in a sequence ( , the number of residues 
preceding it). These are the hidden states ,  of the HMM, and the set of unique paths 
through the states represent all possible amino acid sequences with mass equal to the 
precursor. 
The transition between two states in the HMM is equivalent to an amino acid mass. 
Starting from ,  ( 	0	Da and 	0), the HMM propagates belief across all 
possible paths using the forward-backward dynamic programming algorithm.124 It only 
records a combined (posterior) probability for each state ,  it reaches, regardless of 
how many paths (equal-length, isobaric amino acid sequences) coincide at the state. The 
likelihood of a state at 0 and  depends on the RF estimate at  and the 
likelihoods of neighboring states at 1 and 1. Additionally, it is influenced by state 
transition probabilities representing single amino acid frequencies and dipeptide 
probabilities in the forward and backward directions. The amino acid state transition 
probabilities vary positionally within the peptide, and we incorporated into the HMM the 
expected frequencies of observing an amino acid at either of the N or C-termini or as an 
interior residue. 
The state transition probability matrices were generated based on amino acid 
frequencies in an in silico digested E. coli reference proteome. They could, in practice, be 
based on any sequence database similar to the organism or sample under study. The 
probability of observing methionine was divided between its oxidized and un-oxidized 
forms at a rate (25%) matching that observed in a proteomically identified E. coli peptide 
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data set. (Note that incorporation of an expectation-maximization algorithm for HMM 
parameter estimation would remove the dependence on preexisting sequence or proteomic 
references.) Frequency and transition probabilities were marginalized against nominal 
residue mass, meaning indistinguishable residue pairs I/L, and F/M-oxidation were 
combined. Being carbamylated, lysine was distinct from glutamine. We removed cysteine 
from consideration as the peptides were not alkylated, and disulfide bonding would make 
observation of cysteine-containing peptides exceedingly rare. 
As the length of each true peptide sequence was not known, HMMs were 
constructed for the set of most likely candidate lengths of a particular spectrum. Generally, 
between one and seven models were created for each spectrum. The fragment site 
probabilities were different in each model because the set of possible sequences composing 
each were necessarily disjoint. 
Sequence assignment 
The forward-backward algorithm and HMM construction described above can 
identify the most likely fragment mass states at each position along the spectrum. These 
states only represent which masses likely correspond to a fragmentation site, and they may 
not all derive from the same peptide. There is often not a viable amino acid path through 
all of the most probable states. We use the Viterbi algorithm123,125 on the HMM results to 
obtain the most likely amino acid sequence reconstruction. This moves through the 
fragmentation site HMM posterior probabilities and identifies the single most likely path 
through the set of nodes. Our algorithmic approach is currently limited in that we find, for 
a given spectrum, only the single best path for each putative amino acid sequence length. 
Extending this to the provably correct set of top  paths becomes a more challenging 
problem. 
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De novo sequence scoring and filtering 
Sequence reconstructions were scored, ranked, and filtered to create a final set of 
de novo sequences. The probability that a de novo sequence is correct is equivalent to the 
joint probability that all predicted nodes are correct and all true nodes were predicted. As 
the nodes are not independent, the true probability cannot be easily derived. A simple upper 
bound is given by the Fréchet inequality, equivalent to the probability of the single lowest-
scoring node in a sequence:126 
	 &	 &	… 	&	 , , … , 	
This was often biased in favor of the shorter of two similar sequences when ranking 
reconstructions from a single spectrum. We applied it instead to filter unlikely sequencing 
results, removing all results for a given spectrum if none of the reconstructions surpassed 
a threshold value. In the same manner, we removed spectra without at least one high 
scoring reconstruction, using as a metric the average sequence node score. As detailed in 
the main text, these two filters greatly enriched the fraction of correctly sequenced spectra, 
removing over two-thirds of those that were not sequenced successfully. 
Under the HMM framework discussed above, a spectrum may have a pair of 
probable HMM nodes at the same mass and consecutive sequence positions, ,  and 
, . When, for example, the node at  falls on the true peptide sequence path, any 
potentially correct node at n-1 will have a decreased likelihood due to the incorrect 
, . This effect explains to a large degree the bias toward shorter peptides noted 
above, as the nodes of shorter peptides from a spectrum will have better positional 
resolution. We implemented a node rescoring scheme to address this problem. After 
defining a putative sequence, we removed any incorrect node that shared a mass with an 
on-sequence node. Taking the average node score following node renormalization at each 
 59
sequence position yielded a new sequence score metric. Candidate sequences for each 
spectrum were ranked by this score metric. Empirically, this performed significantly better 
than the two probability-based metrics above, but it was not as effective for filtering. 
Amino acid precision and recall 
We also assigned scores to the individual amino acids of the sequence predictions 
and used these for the construction of the precision-recall curves below. A residue spans 
the gap between two nodes and does not inherently have a score. Following the inequality 
defined above, we set an amino acid confidence score as the smaller likelihood from the 
two nodes defining that amino acid. Amino acids are ranked and sorted by decreasing 
confidence, and we calculate precision and recall values cumulatively for each increasingly 













 is the total number of amino acids across all SEQUEST PSMs in the test set. We 
plot precision versus recall for all values for , where 1  and  is the number of 
all amino acid predictions. A correct amino acid is one that matches both the mass position 
and identity of a residue in the known peptide sequence, allowing for I/L and F/MOxy 
ambiguity. The tradeoff between precision and recall indicates our residue confidence 
score is well-calibrated for ranking the pooled amino acids. 
RESULTS AND DISCUSSION 
We based our strategy to enhance de novo peptide spectrum interpretation on the 
ability of UVPD to efficiently generate C-terminal fragment ion (y ion) series while 
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eliminating N-terminal ions (a, b ions). This strategy required efficient attachment of a UV 
chromophore to the N-terminus of each peptide in order to target them by 351 nm UVPD, 
while avoiding labeling of lysine side-chains that would result in indiscriminant 
chromophore attachment. We describe a sample processing scheme that accomplishes 
these goals and enables UVPD-based de novo peptide sequencing. We also introduce the 
de novo sequencing program UVnovo, as to date there is no de novo sequencing program 
suitable for analysis of 351 nm UVPD mass spectra. 
Lysine capping with carbamylation 
In order to confine AMCA modification to the N-termini of peptides, the epsilon 
amino group on lysine side chains must first be blocked. We have previously employed 
lysine guanidination for this purpose, converting lysines into homoarginines via reaction 
with O-methylisourea in the presence of 7 N ammonium hydroxide.93,114 Here, we improve 
on this strategy and instead convert lysine to homocitrulline via carbamylation. This 
provides a quick and efficient alternative to guanidination for blocking the reactive epsilon-
amino group on lysine side chains. Heating samples at 80 °C for four hours in an 8 M urea 
solution resulted in complete reaction of reactive primary amines on model proteins, 
including the N-termini and lysine side-chains.115 As a proof of concept we evaluated 
carbamylation efficiency on intact myoglobin molecules before and after the carbamylation 
reaction, using direct injections of the intact protein into a high resolution Thermo Orbitrap 
Elite. With nineteen lysine resides and a free N-terminus, myoglobin has 20 amine reactive 
sites (Figure 3.3a). We observed a mass shift of 860.09 Da between the modified and 
unmodified forms, very close to the 860.116 Da expected from complete carbamylation 
(20*43.0058 Da). We estimated to be nearly complete based on the ESI mass spectrum 
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shown in Figure 3.3b and c. A similar analysis of intact ubiquitin (data not shown) also 
revealed complete lysine carbamylation. 
Figure 3.3: Demonstration of virtually complete Myoglobin lysine carbamylation. 
Lysine carbamylation is observed after protein incubation in 8 M urea (4 h at 80 °C). (a) 
Myoglobin has 20 possible carbamylation sites: the protein N-terminus and 19 Lys 
residues. The mass difference of 860.09 Da between (b) unmodified and (c) carbamylated 
myoglobin indicates modification at all 20 sites. High accuracy ESI mass spectra were 
collected on an Orbitrap Elite. 
351 nm UVPD spectra 
Figure 3.4 presents a representative UVPD mass spectrum for a peptide from E. 
coli elongation factor G protein. The clean series of y ions is consistent with 351 nm UVPD 
and demonstrates the effective annihilation of b ions during the activation period (i.e. 15 
laser pulses). The b ions (which contain the N-terminus) retain the AMCA chromophore 
and are susceptible to photoabsorption and dissociation during successive laser pulses. 
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Very few internal fragment ions are observed. While fragment ions are often diminished 
C-terminal to proline, peptide cleavage otherwise produces a comprehensive series of 
observable y ions. 
Figure 3.4: UVPD spectrum of peptide V[AMCA]YSGVVNSGDTVLNSVK[carbamyl]AAR. 
UVPD (3 mJ per pulse, 15 pulses) mass spectrum of charge 2+ Elongation factor G peptide 
V[AMCA]YSGVVNSGDTVLNSVK[carbamyl]AAR from a trypsin-digested E. coli lysate. The 
precursor is labeled with an asterisk. 
In one regard, spectral symmetry is beneficial for low resolution data because b and 
y ion pairs provide the most effective means for correct de novo precursor mass 
assignment.104,108,119,127 The lack of complementary ion pairs and other telltale MS/MS 
signatures of precursor mass in our data precluded effective mass error correction. After a 
baseline correction of systematic error, only 63% of the E. coli lysate spectra we used for 
benchmarking (described below) had a mass within ±0.5 Da of the SEQUEST PSM. In all 
results below, the precursor mass was therefore assigned as the integer nearest the PSM 
mass. 
However, the benefits of the UVPD method for de novo sequencing are twofold, 
and they cannot be overstated. First, with a complete y ion ladder, full-length, gapless de 
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novo reconstructions are frequently attainable for non-trivial peptides. Second, the spectra 
display an ion ladder from only the C-terminus, eliminating the computationally intractable 
antisymmetric path problem (where mirror-image sequences propagate along both N-
terminal and C-terminal ion ladders). De novo algorithms commonly address this problem 
by making imprecise assumptions, such as requiring that b and y ions not share the same 
mass node. Such assumptions are unnecessary with 351 nm UVPD mass spectra. 
UVnovo 
We developed UVnovo to de novo interpret AMCA-treated UVPD spectra. As 
illustrated in Figure 3.2, the UVnovo spectral processing pipeline progresses through four 
main steps for each MS/MS spectrum. Briefly, the spectrum is simplified using a random 
forest (RF) classifier.116 At each integer mass position along the spectrum, the RF merges 
evidence from 30 spectral features to predict whether that position falls at a peptide bond 
of the precursor peptide backbone. Next, a Hidden Markov Model is used to estimate the 
probability that each site corresponds to a true fragment ion.124 Each spectrum is then 
assigned one or more potential sequences using the Viterbi algorithm, with a single best 
sequence generated for each likely spectrum peptide length.125 The candidate de novo 
sequences are scored and ranked using the HMM fragment node probabilities. 
Validation of UVnovo using E. coli lysate 
In order to measure performance on a complex protein sample, we applied the 
AMCA-UVPD strategy on a full E. coli lysate. The lysate was carbamylated, digested, 
derivatized with AMCA, and analyzed via LC-MS/MS with 351 nm UVPD. Spectra from 
triplicate E. coli runs were processed with Proteome Discoverer SEQUEST using the 
Percolator node and allowing a ±1.6 Da precursor mass tolerance. Limiting the results to 
doubly charged precursors and top-ranked matches, 7911 high confidence identifications 
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matching 2983 unique peptide were obtained from the 106,870 spectra collected across all 
three samples. We benchmark UVnovo against these high confidence PSMs using three-
fold cross validation (CV) to maintain independence between training and test sets. 
Each CV repetition was trained independently for UVPD spectral interpretation. 
During random forest generation, 30 predictor variables were automatically identified as 
the most important out of a total space of 407 potential features. Feature scoring and 
selection was largely consistent between the 3 CV repetitions, and 27 of the selected 
features were the same between each of the CV repetitions. These primarily represented 
spectral peaks at specific mass offsets relative to the base position, and as expected, the 
most important feature corresponded with y+ ions. Many of the features have not been used 
in prior de novo software, although the fact that they independently emerged among the 
most important from each of the CV rounds shows their value and the power of an open 
machine learning approach to spectral analysis. 
UVnovo generated a list of sequences for each spectrum, typically with no more 
than seven candidates, and sequences were ranked based on descending confidence score. 
We required a ‘correct’ sequence reconstruction to exactly match its corresponding 
SEQUEST PSM, after allowing for indistinguishable residue pairs I/L and F/MOxidation. No 
sequence gaps or truncations were permitted. 
UVnovo produced correct top-ranked sequences for 47.4% of the E. coli mass 
spectra, and when considering the top three de novo sequences for each spectrum, 59.8% 
had a match to the corresponding SEQUEST PSM (Figure 3.5a). The number of correct 
reconstructions drops substantially with decreasing de novo sequence rank (Figure 3.5b). 
Peptides with correct sequences ranged in size between 6 and 24 amino acids and had an 
average length of 11.0 residues. This compares to an average peptide length of 11.8 from 
the total set of SEQUEST PSMs, only two of which were longer than 24 residues. 
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Exclusion of spectra without high scoring de novo reconstructions dramatically improved 
sequencing precision. This filtered out two thirds of the false positive predictions while 
retaining 85.5% of true predictions, boosting the precision to 66.4% and 80.4% for top one 
and top three de novo sequence sets, respectively (Figure 3.5c,d). Our ability to identify 
correct full length sequences from the majority of the test set demonstrates the benefits of 
AMCA-UVPD for comprehensive and interpretable peptide fragmentation. 
Figure 3.5: UVnovo de novo results for the E. coli lysate UVPD spectra. 
A correct sequence matches the SEQUEST PSM exactly with no gaps. UVnovo scores 
each sequence reconstruction and ranks it relative to others from the same spectrum. (a) 
Number of correct sequences versus peptide length for the top-ranked de novo result and 
for the top three de novo results. (b) Fraction of correct sequences versus de novo rank. 
(c,d) Filtering of low scoring de novo predictions improves sequence-level precision. 5062 
of the original 7911 spectra remain, and over 75% of those removed had no correct match.
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Figure 3.6: UVnovo sequencing error and precision recall of residue predictions. 
(a) Amino acid error versus peptide length for top-ranked de novo sequences from the 
filtered set of higher-confidence predictions. Most sequences are correct with no insertions 
or deletions. Incorrect sequences tend to diverge from SEQUEST PSMs by only 2 residues 
(a single fragmentation site misprediction). Histograms show fractional counts in each 
dimension. (b,c) Amino acid precision-recall for the complete and filtered de novo results. 
AAs are pooled and sorted by residue-level score from (blue) the top-ranked de novo 
predictions for each spectrum or (dashed red) the best match among the top 3 predictions 
for each spectrum. 
For those spectra without a correct full-length identification, the highest scoring 
prediction often differed from its matching PSM at only a single fragmentation site, 
corresponding to a difference of two amino acids. Figure 3.6a displays the frequency and 
extent of amino acid sequencing errors versus peptide length in the filtered set. Over half 
(52.0%) of the misidentified sequences differ from the SEQUEST PSM by only two amino 
acids, meaning that only one fragmentation site per peptide is recognized incorrectly. 
Furthermore, each amino acid in a sequence reconstruction has an associated score. Pooling 
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all residue predictions and sorting by descending score allowed us to plot the amino acid-
level precision and recall of residue assignments, a common metric for de novo algorithm 
performance.104,106,128 In brief, precision is measured as the fraction of correct predictions 
out of all amino acids predictions, and recall is the fraction of all amino acids in the test set 
that are correctly identified. Correct counts must match both the residue assignment and 
mass position along the spectrum. Shown for the total set in Figure 3.6b and the filtered set 
in Figure 3.6c, the UVnovo precision-recall curves confirm high sequence coverage and 
low error at the amino acid-level. 
Figure 3.7: UVnovo and SEQUEST each identify different peptides from co-eluting pair. 
a) UVnovo and SEQUEST both assign the sequence EVEGFGEVFR. b) Spectrum is 
acquired 49 seconds after (a). Here, UVnovo assigns PVNIDIQTIR, conflicting with the 
SEQUEST identification, EVEGFGEVFR. Both sequences are present within the E. coli 
reference database. 
Co-eluting peptides in our data sometimes manifest as differences between the de 
novo sequence and SEQUEST PSM for a spectrum. In some cases, this resulted in a hybrid 
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de novo sequence blended from the two precursor peptides. Ideally, however, the differing 
de novo results complement the SEQUEST identification, and both are correct. As an 
example, Figure 3.7 presents a pair of co-eluting peptides observed across two spectra. 
Both SEQUEST and UVnovo identified the first spectrum as EVEGFGEVFR (1383.62 
Da). The second spectrum, acquired 49 seconds later in the same injection, took the same 
SEQUEST PSM, while UVnovo assigned the sequence PVNLDLQTIR (1383.73 Da). 
Both are present within the E. coli sequence database, though the latter was not included 
in the SEQUEST search due to the presence of proline C-terminal to the tryptic arginine 
residue. We also observed other ‘incorrect’ de novo identifications with exact matches to 
semi-tryptic E. coli peptides. Such examples indicate inflated error rate estimates in our 
results and point to the power of de novo methods in general for identifying unanticipated 
peptide variants. 
Finally, we note that our results compare favorably to the performance of leading 
de novo sequencing algorithms on high-resolution datasets in general, although specific 
comparisons on this dataset were not feasible due to the nature of the modifications and 
ion series employed here. For example, while UniNovo was designed to interpret novel 
fragmentation spectra, it does not permit user-defined peptide modifications or custom 
protease specificities.100 More generally, most available de novo software is designed to 
recognize peptide fragmentation patterns generated through HCD, CID, or ExD, very 
different from the single y ion series we observe, and many of these programs address the 
antisymmetric path problem with assumptions that would negatively affect results for 
spectra with unambiguous directionality. Nonetheless, by employing stringent 
benchmarking criteria (e.g., requiring complete peptide sequence predictions that exactly 
match corresponding database PSMs), our data show that UVPD/UVnovo accurately 
 69
identifies peptide sequences in complex samples and cell lysate contexts through a fully de 
novo sequencing approach. 
CONCLUSIONS 
We describe new experimental methods and the UVnovo software package for de 
novo peptide sequencing by UVPD. High efficiency carbamylation blocks lysine side 
chains, and subsequent tryptic digestion and N-terminal peptide derivatization with the UV 
chromophore AMCA yields peptides susceptible to 351 nm ultraviolet activation. The 
UVPD mass spectra, primarily composed of y ions, are particularly well suited for de novo 
sequencing. As illustrated in the present study, 351 nm UVPD alleviates two of the 
fundamental limitations for de novo sequencing of standard spectra: incomplete or biased 
peptide sequence coverage, and spectral symmetry due to observation of both N- and C-
terminal ions. Because of the proclivity to generate abundant y ions, the spectral peaks are 
easier to interpret, and the antisymmetric path problem is nonexistent. Additionally, the 
comprehensive peptide backbone cleavage of UVPD provides the means to reconstruct full 
or nearly full sequences for most high-quality peptide spectra. 
Development of UVnovo was motivated by a lack of appropriate tools for analysis 
of 351 nm UVPD peptide mass spectra. UVnovo combines random forests and Hidden 
Markov models to simplify and interpret UVPD fragmentation spectra, enabling the de 
novo sequencing of thousands of peptides from an E. coli lysate at high confidence. 
UVnovo performance, seen here for low-resolution ion trap spectra, broadly matches that 
of leading de novo programs on high-resolution MS/MS spectra. Due to the full sequence 
coverage provided through UVPD, our workflow offers unprecedented capability for full-
length peptide de novo sequencing. Further refinement of the UVnovo algorithm is 
underway and will capitalize on integrating CID and UVPD paired spectra. 
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Chapter 4: UVnovo de novo sequencing of paired CID/UVPD spectra  
We describe collection and de novo peptide sequencing of matched CID and 351 
nm UVPD spectral pairs.* Each precursor ion is isolated twice, the instrument switching 
between CID and UVPD activation to obtain a complementary MS/MS pair. We generalize 
UVnovo to concurrently synthesize information from both spectra into a single fusion 
spectrum, from which it generates de novo sequence predictions. Through machine 
learning, UVnovo shifts the burden of fragmentation model definition from the 
programmer to the machine, and opens up the model parameter space for inclusion of 
nonobvious features and interactions. Applied to a benchmark E. coli lysate CID/UVPD 
dataset, the program reconstructed correct full-length de novo sequences for 83% of the 
spectral pairs. For 70% of the pairs, this was the top-ranked de novo prediction. This 
chapter presents the CID/UVPD workflow and demonstrates the capacity of UVnovo for 
accurate and high-throughput de novo peptide sequencing. 
INTRODUCTION 
The adoption of high throughput bottom-up mass spectrometry for proteomics has 
accelerated rapidly in the past decade. This is largely driven by improvements in both 
instrumentation and software interpretation of protein mass spectral data, and more spectra 
of higher quality may be identified from an experiment than ever before. However de novo 
peptide sequencing, where spectra are identified without use of a reference sequence 
database, has not seen a commensurate advancement. Limitations inherent in most spectra 
prevent accurate and full-length de novo sequence assignment for bottom-up proteomics 
                                                 
* This chapter represents a manuscript in preparation with contributions from A. P. Horton, S. A. 
Robotham, J. R. Cannon, D. D. Holden, E. M. Marcotte, and J. S. Brodbelt. S.A.R. and J.S.B. designed the 
experimental workflow. S.A.R. performed the sample preparation and data collection. D.D.H. modified the 
instrument control software. A.P.H. designed and developed the UVnovo analysis software and wrote the 
manuscript. 
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workflows, and the gap is being filled with ever more elaborate database search workflows 
and custom processing pipelines. 
The previous chapter illustrates how 351nm UVPD can alleviate two major 
obstacles to successful de novo sequencing: incomplete or biased peptide sequence 
coverage, and spectral symmetry due to observation of both N and C-terminal ions. We 
now describe modifications to a Thermo Velos Pro ion trap mass spectrometer that allow 
collection of CID/UVPD spectral pairs and demonstrate high-throughput collection of 
CID/UVPD pairs. The greater fragment ion diversity in CID spectra can be a valuable 
complement to the simple y ion series generated through UVPD, and the combination of 
UVPD and CID spectra offers superior de novo sequencing performance compared to use 
of UVPD alone. 
The use of paired spectra has over a decade of precedence for de novo sequencing. 
Matched spectra, generally pairs or triplets produced from different precursor activation 
methods, contain complementary information that can substantially improve sequencing 
performance. Savitski et al., in 2005, described “proteomics-grade” de novo sequencing 
from high resolution CID/ECD spectral pairs, and other groups followed.129 Many software 
tools now support sequencing of paired or triplet spectra, PEAKS and pNovo+ being the 
most popular.99,100,102,130–134 These programs are each limited to one of a few combinations 
from CID, HCD, ETD, and ECD spectra. Here we report on UVnovo improvements that 
provide the capability to merge information from multiple spectra of the same peptide. 
We initially developed the UVnovo software for de novo interpretation and 
sequencing of 351 nm UVPD mass spectra. UVnovo differs from most other de novo 
sequencing programs in how it models and interprets fragmentation spectra. Most are 
developed around the offset frequency function (OFF), which represents a descriptive 
statistical model for understanding and interpreting peptide fragmentation.108 These 
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programs may use a directed graph structure to capture simple dependencies between the 
expected fragmentation peaks or features (ex. b ions, neutral losses).103 The models are 
typically hand-tuned or, at least, provided a concrete set of features and dependencies, and 
for well-characterized type of spectra they can perform quite well. 
In a departure from the frequency-based statistical models, UVnovo employs a 
machine learning approach and uses a random forest (RF) algorithm to automatically learn 
from and interpret mass spectra. RF is a popular and powerful algorithm that combines the 
predictions of many individual decision trees into a single ensemble.116 Decision trees and 
random forest ensembles can exploit a much larger space of features and feature 
interactions when compared to classical statistical models.121 The de novo sequencing 
program Novor employs this advantage through use of two large decision trees for spectral 
interpretation and scoring.106 UVnovo, too, combines and utilizes spectral features at a 
scale that is combinatorially impractical with OFF-based models. 
While Novor uses the same set of spectral features regardless of activation type, 
however, UVnovo selects automatically those it finds most important from a much larger 
space of potential features. In this regard UVnovo follows the work of Datta and Bern, 
whose spectrum fusion algorithm used the OFF to learn features important for paired CID 
and ETD spectra interpretation.119 It then modeled simple feature dependencies and 
constructed effective tree-augmented networks for making predictions. Unfortunately, 
their algorithm was only presented as a demonstration of the automated supervised learning 
technique and was not released for general use. UniNovo also applies the OFF in a similar 
scheme for automated fragment ion learning.100 It does not permit user-defined peptide 
modifications or custom protease specificities, therefore precluding its use for UVPD 
spectra of AMCA-derivatized peptides. 
 73
The generalized UVnovo framework for learning novel fragmentation patterns 
removes a great burden from the programmer and obviates the need for explicit definition 
of the fragment ions, their importance and correlation structure. We apply UVnovo to 
complementary pairs of UVPD and CID spectra and show that de novo sequencing 
performance is greatly improved relative to that for individual spectra. 
METHODS 
Materials 
We purchased Trypsin Gold, mass spectrometry grade, from Promega (Madison, 
WI, USA), LC-MS grade acetonitrile and water from EMD Millipore (Darmstadt, 
Germany), and phosphate buffered saline (PBS) and dimethyl sulfoxide (DMSO) from 
Thermo Fisher Scientific Inc. (San Jose, CA, USA). Sulfosuccinimydyl-7-amino-4-
methyl-coumarin-3-acetic acid (Sulfo-NHS-AMCA) was purchased from Pierce 
Biotechnology (Rockford, IL, USA). E. coli lysate was graciously donated by Dr. M. 
Stephen Trent’s research group at the University of Texas at Austin. 
Instrumentation for paired CID/UVPD collection 
We used a Thermo Velos Pro dual linear ion trap mass spectrometer (Thermo 
Scientific, San Jose, CA, USA*) coupled to a Coherent 351 nm excimer laser (Coherent, 
Santa Clara, CA, USA) for UVPD ion activation in the ion trap.117 Collection of paired 
CID/UVPD data required modification to the standard instrument runtime procedures, 
accomplished with custom scripts in Thermo Fisher Scientific’s proprietary ion trap control 
language (ITCL).135 
Briefly, each selected precursor ion was isolated twice in succession, first for 
activation by CID and again for UVPD. By setting the NCE parameter to a value above 0, 
precursors for CID scans were retained in the high-pressure cell (HPC), and the laser was 
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not triggered. The CID fragment ions were transferred to the low-pressure cell (LPC) for 
detection. Setting the NCE value to 0 directed precursor ions to the low-pressure cell 
(LPC), and the laser was pulsed for UVPD activation. 
Sample preparation for UVPD analysis 
We used whole cell E. coli lysate for development and testing of the paired 
UVPD/CID acquisition and sequencing workflow presented here. Sample preparation and 
N-terminal chromophore peptide modification were performed as described previously.77 
E. coli lysate was carbamylated to block the reactive primary amines of the lysine side-
chains by mixing 50 μg of lysate in 50 mM sodium carbonate with 8 M urea and heating 
for 4 hours at 80 °C. The resulting carbamylated proteins were then buffer exchanged into 
PBS to remove urea and subsequently digested using trypsin at 37 °C overnight. After 
digestion, 25 µL of 20 mM AMCA in DMSO was added to the solution and kept in the 
dark overnight at room temperature. A C18 SPE cartridge was used to clean the samples 
and remove residual AMCA. Finally, the samples were dried and reconstituted for LC-
MS/MS in 98% water / 2% acetonitrile with 0.1% formic acid. 
LC-MS/MS analysis and acquisition of a CID/UVPD dataset for benchmarking 
Peptides were separated by reverse phase chromatography using a Dionex NSLC 
3000 nanoLC (Thermo Scientific; Waltham, MA, USA) interfaced to the UVPD-enabled 
Thermo Velos Pro described above. Samples eluted over a 360 min gradient, starting with 
3% B and increasing to 50% B and using a flow rate of 300 nL/min. Mobile phase A was 
water with 0.1 % formic acid (v/v), and mobile phase B was acetonitrile with 0.1% formic 
acid (v/v). Approximately 5 µg of peptide mixture was loaded on a 15 cm column, packed 
in-house with C18 stationary phase 3.5 µm particles of 140 Å pore size. Five precursor 
ions were selected following each MS1 scan. Fragmentation switched between CID (NCE 
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35, 10 ms) and UVPD (15 pulses at 500 Hz and 3 mJ per pulse), and a complementary pair 
of MS/MS were generated for each selected precursor ion. 
UVnovo 
UVnovo is implemented in MATLAB (version R2013a), and de novo sequence 
prediction proceeds through four main steps: 
Spectrum fusion: Information from all spectra of a precursor ion is synthesized into a single 
fusion spectrum, where peak ‘intensity’ scores reflect the predictions of a random 
forest model trained to recognize peptide fragmentation sites. 
HMM prediction refinement: Fusion spectrum predictions are put into a hidden Markov 
model (HMM) framework and integrated with knowledge of amino acid 
relationships and valid mass transitions. This model assigns a probability 
distribution across the valid prefix masses for each successive peptide prefix 
fragment. A separate HMM is created for each likely sequence length of a precursor 
peptide. 
De novo sequence prediction: A greedy best-path algorithm identifies the most likely 
peptide sequence spanning each HMM. 
Sequence scoring: Candidate peptide sequences are scored and ranked relative to others 
from the same precursor. 
Terms and notation 
Subsequent use of the term mass indicates a value with nominal mass units, 
equivalent to the integer count of protons and neutrons composing the referred to species. 
The conversion from Daltons is imprecise, and we take the product, to the nearest integer, 
of Dalton mass and a mass defect normalization factor (1/1.000468) to obtain a nominal 
mass. 
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The peptide bare mass, , is the mass of residues composing a peptide, without the 
water and proton (19 Da) of the conventional peptide mass. Each interior position of a 
peptide is addressed by its N-terminal prefix mass, , or its suffix mass, , where 
. Here, a fragmentation site is the position of a cleavage between two 
consecutive amino acids, its value given as the integer mass sum of residues N-terminal to 
that cleavage site. 
Spectrum fusion 
The spectrum fusion stage applies a random forest predictive model for 
interpretation of spectra deriving from a common precursor, in effect deconvoluting the 
fragmentation patterns of multiple MS/MS into a single spectral representation of likely 
peptide fragmentation sites. While the following description assumes CID/UVPD spectral 
pairs, the same implementation is used regardless of spectral type or number of different 
activation methods applied. 
The random forest is first trained against matched CID and UVPD spectral pairs to 
recognize MS/MS ion signatures indicative of peptide fragmentation sites. During 
spectrum fusion, the model then predicts at each interior peptide location  whether 
that mass represents a true fragmentation site. Each prediction is based on a small set of 
important features drawn from across the spectral pair, this set learned during the 
aforementioned RF training procedure. 
Before RF training or prediction, spectra are normalized so that values of locally-
prominent peaks are more consistent, both across a spectrum and between spectra from the 
same activation method. Peaks are ranked by descending intensity and then assigned to 
unit-width mass bins, the lowest rank (most intense) taking precedence in case of collision. 
Broad differences in peak intensity along a spectrum are reduced by subtracting the 
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minimum peak rank within a ± 50 Da sliding window, with values then divided by the 
precursor mass. This neighborhood-adjusted rank score replaces peak intensities, and 
spectral fusion is performed using these normalized spectra. 
The random forest takes as input a feature vector for each mass position  where 
a prediction is to be made. The initial feature space for paired spectra modeling includes 
811 variables, though only a subset are used for prediction. Through an iterative feature 
selection process, UVnovo identifies this smaller set as those most valuable for 
constructing an effective RF. Trained models use 30 features in the present study. RF 
training and feature selection is discussed below and includes a description of the 811 
initial features. In short, the feature vector for an RF prediction at  primarily comprises 
peaks at specific mass offsets relative to the  and , from both of the normalized 
CID and UVPD spectra. 
The fusion spectrum is generated as follows. A feature vector is constructed for 
each in a peptide and passed to the RF. The 600 decision trees in the ensemble 
individually predict whether the  does (1) or does not (0) represent a fragmentation 
site, and the mean of the 600 binary predictions becomes the fusion spectrum score at that 
mass position. Repeating this for each integer mass within a peptide produces the fusion 
spectrum for that spectral pair. 
De novo sequencing of fusion spectra 
Details of the hidden Markov modeling, de novo sequence assignment and scoring 
are described in full in the methods section of Chapter 3. We provide an overview here. 
A hidden Markov model framework integrates the fusion spectrum predictions with 
knowledge of amino acid relationships and valid mass transitions.136 An HMM is created 
for each likely sequence length  of the precursor and describes all possible length  
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sequences with mass equal to the precursor. Every possible fragmentation site is 
represented by a node in the HMM, and nodes are indexed by  and the count of 
preceding residues. A path through the HMM defines a viable peptide sequence, and the 
nodes (or hidden states) along the path are each separated by the mass of an amino acid. 
As co-localized theoretical cleavage sites share the same node (e.g. PEA|S and APE|S), the 
HMM only provides a prefix mass probability distribution for each sequence fragment site, 
not the probability for every path through the model. 
The single most likely path through an HMM is identified using the Viterbi 
algorithm.124 Due to the mass resolution limitations of ion trap spectra, UVnovo does not 
distinguish between the residue pairs I/L and F/Moxidation. De novo sequence predictions 
were scored as described in Chapter 3. 
Random forest training and parameterization 
The 811 initial features comprise 404 peak features from each normalized spectrum 
and 3 features derived only from  and . The first group includes peak features 
corresponding to b- and y- ions. However, these common fragmentation products are not 
explicitly encoded and are instead recognized automatically through the machine learning 
process. 
The peak features are extracted from four ranges in each normalized spectrum, one 
centered at each of the charge 1+ and 2+ prefix mass  and suffix mass  positions. 
Each range spans the -50 to +50 Da window around its center, and includes as a feature the 
normalized rank score for each of the 101 included peaks. For example, the charge 2+ prefix 
set contains a feature for each position 25	m/z  to 25	m/z  with a 
0.5 m/z step size. The three derived features are calculated as: ⁄ ; 100⁄ ; and 
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100⁄ . Respectively, these represent the position within the peptide, the 100 Da 
region containing the prefix mass, and the 100 Da region containing the suffix mass. 
UVnovo applies a backward variable elimination method for feature selection. It 
trains an initial RF using all 811 features, which are then ranked by their predictive 
importance in the trained model. The RF is discarded and trained anew using only higher-
ranked features from the previous round. This process is repeated thrice more, yielding a 
final RF trained on 30 features and containing 600 decision trees. 
We chose to use 30 features for constructing the CID/UVPD random forest 
models after completing a sweep across  from 10 to 55 (step size 5). RF parameter choice 
can be evaluated easily during model training. Each decision tree in an RF ensemble omits 
roughly a third of training examples during its construction. Evaluating for each tree the 
examples that tree left out during training (out-of-bag, OOB) provides an estimate of the 
RF classification error. With this OOB error metric, we observed how RF performance 
changes with different feature sets. RF were constructed for each set of the top  features, 
as ranked by a preliminary RF of 60 features. We repeated this experiment five times, using 
a different random number generation seed for each of the replicates. This ensured 
reproducibility and limited some of the randomness of within-replicate comparisons for the 
different values . 
UVnovo is trained using examples drawn from a representative set of CID and 
UVPD pairs. Defined by the corresponding PSMs, the collection of true fragmentation sites 
composes the positive RF training examples. A set of negative cases was created by 
randomly shifting each of the real fragmentation sites. Therefore, the number of positive 
and negative examples is balanced 1:1 during the UVnovo training regime, and the OOB 
error approximates the misclassification rate on these examples. Therefore, this metric does 
not directly reflect RF classification error on actual spectra. During spectral fusion, the RF 
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is applied at every potential precursor fragmentation site, where negative predictions are 
expected to outnumber true fragmentation sites by about 100:1. However, weighting the 
positive and negative examples to better match expected rates of observation degraded the 
subsequent HMM performance and de novo accuracy (data not shown). By constructing 
RF with equal representation between positive and negative training examples, the RF is 
skewed toward more false positive prediction error. This is desired because the HMM de 
novo sequence assignment is much more sensitive to 'missing' peptide fragmentation sites 
in the RF fusion spectrum. 
Benchmarking 
SEQUEST 
We processed the E. coli CID/UVPD spectra, acquired over three injections, using 
the SEQUEST and Percolator nodes in Proteome Discoverer v. 1.4 (Thermo Fisher 
Scientific, San Jose, Ca, USA). Both N-terminal AMCA and lysine carbamylation were 
required as fixed modifications, and optional methionine oxidation was allowed. Spectra 
were searched against a sequence database that included the UniProt E. coli strain K12 
reference proteome and common contaminants (from MaxQuant website, 
http://maxquant.org/contaminants.zip). From the resultant PSMs, we established a high 
confidence dataset for UVnovo training and validation. We limited this set to spectral pairs 
from doubly charged precursors with high confidence PSMs (Percolator false discovery 
rate <%1) with theoretical precursor mass within ± 1.5 Da of the observed value. 
Additionally, only PSMs for the CID spectra were considered. 
UVnovo 
We evaluated UVnovo de novo sequencing performance on the CID/UVPD 
spectral pairs as well as on the isolated sets of CID and UVPD spectra. Using a 3-fold cross 
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validation (CV) regime, we were able to test performance against all PSMs while 
maintaining independence between the data used for training and testing. Spectra were 
divided, based on their assigned peptide sequence, into three partitions. In each of the three 
CV rounds, spectra and PSMs from two of the partitions were used for training an RF, with 
which UVnovo used for sequencing ‘unknown’ spectra from the remaining partition. 
Due to the low resolution afforded through ion trap analysis, the instrument-defined 
isolation windows and precursor masses often vary greatly from that of the monoisotopic 
parent peptide. We therefore performed the RF interpretation and de novo sequencing three 
times for each spectral pair, once using the observed mass and again at -1 Da and +1 Da 
from the observed mass. 
The UVnovo sequence predictions for a given precursor were ranked by an HMM-
derived score metric and compared against the corresponding SEQUEST PSM. To be 
considered correct, each residue in the full-length PSM corresponded exactly in position 
and mass to a residue in the de novo sequence. In other words, no sequence gaps were 
allowed, and ambiguous residue pairs I/L and F/Moxidation were treated as equivalent in the 
comparison. 
Results and Discussion 
E. coli lysate was carbamylated at all primary amines and digested with trypsin. 
With lysines blocked through carbamylation, subsequent peptide modification installed 
AMCA at each newly generated peptide N-terminal primary amine. Derivatization with 
this UV chromophore rendered peptides susceptible to 351 nm UV photoactivation. 
ESI-MS/MS was performed using a dual cell linear ion trap mass spectrometer 
equipped with a 351 nm laser. Following each MS1 survey scan, CID/UVPD spectral pairs 
were acquired for each of five selected precursors. The generation of UVPD/CID spectra 
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required modification of the ion trap control software. This instructed the instrument to 
switch between CID in the high-pressure cell and UVPD in the low-pressure cell for 
alternating scans. 
UVPD of AMCA-modified peptides produces spectra with a strong y ion series. 
351 nm photoactivation induces cleavage of the C–N peptide bonds and generates b- and 
y-type fragment ions. The b ions retain the N-terminal chromophore and are consequently 
annihilated with repeated laser pulses during UVPD, while the y ions were not activated 
further and survived in the trap. CID spectra from the same peptides display conventional 
b and y ions, the b ions shifted by +215 Da, the mass of AMCA. Figure 4.1 shows matched 
CID and UVPD spectra for peptide E[AMCA]LVTAAK[carbamyl]LGGGDPDANPR identified 
from E. coli lysate. 
Figure 4.1: CID and UVPD spectra for E. coli peptide ELVTAAKLGGGDPDANPR.  




Spectra, individual or paired, were transformed using a random forest classifier into 
a single vector of prediction scores for each potential N-terminal fragmentation site. High-
scoring positions in the resultant fusion spectrum ideally manifested as a complete and 
clean ‘sequence ladder’ traversal of the parent peptide in the N- to C-terminal direction. 
Constructed from this fusion spectrum, a hidden Markov model put the precursor into a 
framework from which a peptide sequence most descriptive of the data was identified and 
scored. 
Multiple sequence predictions for a precursor were generated, one for each likely 
peptide length. This was repeated for each mass within ±1 Da of the observed precursor. 
All sequence predictions for a given precursor were then ranked by the HMM-derived 
score. 
Random forests for CID and UVPD spectral fusion 
Random forests are generally robust to small changes in parameterization and have 
a paucity of tunable parameters relative to most other machine learning algorithms. These 
strengths, combined with their generally exceptional performance, make random forests 
among the most popular machine learning algorithms. As with most, however, feature 
selection still presents a challenge. When presented a surfeit of unimportant features, use 
of an optimal subset will improve RF time and space efficiency and can reduce prediction 
error. 
UVnovo applies an iterative 'backwards variable elimination' approach for feature 
selection, by which it winnows the total set of 811 down to a final set of 30 used in 
production, on RF ensembles grown to 600 trees. The choice of 30 features reliably 
produced among the most performant CID/UVPD random forests, as measured by OOB 
error (Figure 4.2). 
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Figure 4.2: Random forest OOB error versus number of features used for training. 
Random forests for CID/UVPD spectral pairs were trained varying the number of features 
used during construction. Black bars show the average of 5 replicates (diamonds). 
Performance drops with fewer than 30 features as useful predictors are removed. 
UVnovo benchmarking on E. coli lysate 
51,525 UVPD/CID spectral pairs (103,050 MS2 spectra) were collected across 
three replicate injections. We processed the spectra using Proteome Discoverer SEQUEST 
with the Percolator node and identified, for charge 2+ CID/UVPD pairs, a set of 4616 high-
confidence PSMs covering 1842 unique peptides. These 4616 pairs were applied for 
UVnovo testing, using 3-fold cross validation (CV) to maintain independence between 
training and testing examples. UVnovo generated predictions for each at its observed 
precursor mass and additionally at -1 Da and +1 Da from observed. This was required, as 
43% of pairs diverged from the assigned PSMs by ±1 Da. 
Comparison of de novo predictions to SEQUEST PSMs 
We benchmarked UVnovo predictions from the CID/UVPD spectral pairs against 
the corresponding SEQUEST PSMs, counting a de novo sequence as correct if it matched 
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exactly the PSM, with no gaps allowed. This is a more stringent criterion than commonly 
used for de novo benchmarks. We additionally compared UVnovo performance on paired 
spectra to that using only the CID or UVPD scan subsets. Results are presented in Table 
4.1 and Figure 4.3. 
Table 4.1: Count and frequency of correct de novo sequences by descending UVnovo rank. 
Results show performance of UVnovo using CID/UVPD spectral pairs or the individual 
CID or UVPD spectrum of each pair. The total set contains 4616 charge 2+ paired spectra 
examples from E. coli lysate with corresponding high confidence SEQUEST PSMs. 
Frequency describes the fraction of the 4616 with a correct prediction at each UVnovo 
rank. Correct sequence predictions match the full-length PSM with no gaps allowed. I/L 
and F/Moxidation residue assignments are treated as equivalent. 
Each of the 4616 CID/UVPD examples in the E. coli benchmark was provided 
potentially several putative de novo sequence assignments, and the predictions were scored 
during the sequencing process and ranked once complete. The top-ranked UVnovo 
sequence correctly matched the corresponding PSM for 3258 (70.6%) of the paired 
CID/UVPD spectra. In contrast, UVnovo sequencing on the individual spectral types 
produced only 1822 (39.5%) and 2395 (51.9%) correct top-ranked predictions, for CID and 
UVPD respectively. When including the three best scoring de novo predictions for each 
precursor, UVnovo correctly sequences 82.5% (CID/UVPD), 52.7% (CID) and 69.7% 
 86
(UVPD) of the E. coli examples. There is substantial overlap in these correct assignments 
(Figure 4.3e). 
Figure 4.3: UVnovo results for paired and individual E.coli lysate spectra. 
(a-c) Count of correct sequence reconstructions versus peptide length from the benchmark 
set of 4616 spectral pairs. Correct de novo sequences match the corresponding high 
confidence SEQUEST PSM, with no gaps allowed. Sequencing of (a) paired CID/UVPD 
outperforms that using only the (b) CID or (c) UVPD subset of spectra. (d) Fraction and 
cumulative fraction of correct sequences recovered by descending UVnovo prediction 
rank. Rank correlates well with prediction accuracy. (e) Overlap [counts] of correct top-
ranked sequences between the paired, CID, and UVPD predictions. 
The length of SEQUEST PSMs averaged 11.4 residues across the dataset, and 
correct top-ranked de novo reconstructions from the CID/UVPD and UVPD-only results 
averaged 10.9 residues (Figure 4.3a,c). The CID were shorter on average, at 10.2 residues 
(Figure 4.3b). UVnovo correctly sequences peptides up to 24 residues in length, the largest 
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in our dataset, and four of the six peptides with at least 23 residues were identified by their 
top-ranked CID/UVPD result. To compare, none were identified in the CID analysis and 
only two in the UVPD. 
These results show the advantage of UVPD for de novo sequencing, compared to 
CID, and the largest benefits are realized through synthesis of both CID and UVPD spectra, 
whereby UVnovo can harness the best properties of each activation method. 
UVPD provides comprehensive fragmentation and sequence directionality 
UVPD fragmentation occurs consistently across a whole peptide, and the resulting 
spectra provide better sequence coverage than seen from CID. This characteristic is 
essential for successful full peptide sequencing and accounts for much of the difference in 
CID and UVPD performance. 
Additionally, the absence of strong N-terminal ions in UVPD spectra eliminates 
one of the central problems in standard de novo analysis. Known as the ‘asymmetric path 
problem’, confusion of ion series directionality can lead to inversions in the assigned de 
novo sequence. This is a factor for all fragmentation methods which generate symmetric 
pairs of N and C-terminal ions,98 and it is a particular issue for interpretation of CID spectra, 
due to the presence of symmetric b and y ion series. No commonly used proteomics 
workflows for de novo sequencing avoid this problem, though various specialized labeling 
and instrumentation methods have been developed to address the issue.87,137 As presented 
here, our AMCA-derivatization and 351nm UVPD workflow offers another way to 
overcome this problem. 
CID complexity complements UVPD simplicity 
The complexity of CID spectra can be beneficial in combination with the 
interpretability of UVPD spectra, and the additional b ions and neutral losses substantiate 
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evidence for true fragmentation peaks. The symmetry between b and y ions can, detrimental 
on its own, is effective for inference of the MS/MS precursor mass in UVnovo. UVPD 
spectra, lacking N- and C-terminal ion symmetries, do not provide such a means. The 
symmetries in CID spectra are modeled automatically during RF construction as 
interactions between important features, for example those representing b and y ion peaks. 
The symmetries then influence spectral fusion fragment site predictions. When initialized 
with an incorrect precursor mass, the symmetric features will be misaligned. True 
fragmentation sites usually score lower, as will the subsequent sequence predictions. 
Therefore, sequence predictions made using the correct precursor mass will typically rank 
higher for interpretations involving CID spectra. 
Similarly, discrimination between ions of co-eluting peptides is difficult or 
impossible when using only UVPD spectra, and this can lead to chimeric sequence 
predictions spanning the fragmentation sites of two or more peptide species. CID 
symmetries can again be useful and here provide a means to separate peptide ions from 
species of different mass, sometimes enabling de novo sequence generation for both. For 
example, UVnovo recovers from a single CID/UVPD pair the sequences 
'TENLYILPASQTR' and 'VYDALEVQNGNER'. Both appear as tryptic peptides in the E. 
coli sequence database and differ by one unit mass (0.92 Da). The b and y ion symmetries 
manifest differently for each and enable correct sequencing for both. Neither was identified 
when either of the CID or UVPD where processed alone. 
Future improvements 
These results for paired spectra are comparable to the current state of the art in de 
novo peptide sequencing. When considering that the data was collected on a low resolution 
ion trap mass spectrometer, this becomes particularly impressive and illustrates the benefit 
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of 351nm UVPD, stand-alone or complemented with a second activation method, for de 
novo analysis. High resolution mass spectrometry is considered by many to be 
“exceedingly important” for accurate de novo sequencing,86 and we expect translation of 
our methods to high resolution CID/UVPD acquisition and analysis would further improve 
de novo sequencing performance. As a concrete example, the use of accurate precursor 
mass provides a simple filter for database search results. UVnovo could apply a similar 
mass filter and flag for removal or resequencing any prediction more than 5 ppm different 
from the precursor mass. In the current E. coli experiment, this mass filter would catch 
74.5% of the incorrect CID/UVPD results. 
Accurate precursor mass also allows amino acid compositional analysis techniques 
that improve whole sequence accuracy,138 and can help fill short sequence gaps. Collection 
of high resolution MS/MS spectra can provide even more benefit to de novo sequencing 
platforms. The Vonode software, for example, uses fragment ion mass accuracy for scoring 
short sequence tags within a peptide.139 
In our data, nearly half of the incorrect top-ranked CID/UVPD sequence 
assignments differ at only one fragment site from the corresponding PSM. Both residues 
flanking this misprediction are therefore incorrect. High resolution MS/MS spectra, or even 
an accurate precursor mass, would help substantially in correcting these point errors. It 
would also greatly aid local sequence confidence scores and our ability to fill gaps with the 
correct residues. 
CONCLUSIONS 
We have generalized UVnovo to work with matched MS/MS produced through any 
combination of precursor activation methods, demonstrating here its application on 
complementary CID/UVPD spectral pairs. Provided a set of training examples, UVnovo 
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effectively learns from and then utilizes the best properties of each activation method for 
spectral interpretation. We are not aware of any other software that provides this capability. 
The initial state of UVnovo is agnostic to all fragment ion types and any expected 
patterns or correlations between ions (e.g. neutral losses). Instead, it identifies these 
features automatically during construction of a random forest classifier. This model is then 
used for interpretation of unknown spectra. 
In the case of paired CID/UVPD spectra, the UVnovo random forest model 
synthesizes evidence from both to derive stronger predictions of peptide bond location 
(fragmentation site) than either spectrum could provide on its own. UVPD provides 
comprehensive fragmentation coverage and a clear directionality for ion series, while the 
symmetries and redundancies in CID spectra are necessary for precursor mass assignment 
and improve fragmentation site. 
UVnovo generated correct full-length de novo sequences for 83% of CID/UVPD 
spectral pairs, in an E. coli lysate dataset with charge 2+ high-confidence PSMs. These 
results, obtained from low-resolution ion trap mass spectra, demonstrate the effectiveness 
of a CID/UVPD paired spectra workflow for de novo peptide sequencing. Furthermore, 
with the software improvements presented herein, UVnovo now provides a means for de 
novo interpretation of matched MS/MS generated through any combination of ion 
activation methods. Continued development of UVPD workflows, on high resolution 
instrumentation and perhaps using alternatives to CID, will offer exciting prospects for the 
future of de novo proteome analysis. 
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Conclusions 
The theory of a humoral immunity mediated by serum antibodies was proposed 
over a century ago, though only now can we characterize the individual antibodies 
composing the serological response to vaccination or infection. Our methods for serum 
antibody repertoire profiling and VH:VL sequence pairing open an unprecedented view 
into the nature of the adaptive immune system and provide fresh insight on repertoire 
organization and diversification, immune system development and memory, and 
serological repertoire dynamics in both health and disease. Applied to medicine, these 
techniques will offer powerful tools for disease diagnostics and monitoring, vaccine 
development  and efficacy studies, and therapeutic antibody discovery. 
Antibodies are the primary effectors of the B cell adaptive immune response, and 
as such, direct observation of the serum repertoire is paramount for delineating the 
response. This has proven difficult because an individual’s antibody repertoire 
encompasses a large diversity of non-germline encoded proteins. We were instrumental in 
developing methods for the high throughput sequencing of B cells and mass spectrometry 
of affinity purified serum antibodies, using the individualized antibody sequence database 
for identification of the antibody spectra. 
Challenges specific to antibody repertoire proteomics preclude the use of standard 
analysis methods and motivated our development of novel tools and approaches for 
interpretation of human polyclonal antibody repertoires. In particular the process of 
antibody sequence generation and diversification, through which conserved gene 
framework regions are interspersed with variable complementarity determining regions 
(CDRs) and mutated, leads to an enormous expansion of highly similar but distinct 
antibody proteins. The very similar nature of the resultant peptides, where thousands may 
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share the majority of their sequence, brings unique difficulties to proteomic interpretation. 
In particular, standard peptide mass spectra often lack sufficient fragment ion coverage to 
unambiguously identify CDR-H3 peptides. 
I implemented the UVnovo package for de novo sequencing of UVPD spectra and 
later generalized it to work with any combination of various spectral types. Constructed 
around a random forest machine learning framework, UVnovo automatically learns from 
annotated training examples how it can best interpret future unknown instances of the same 
spectra types. This provides a flexible and powerful means for synthesizing information 
from any number of complementary spectra, and as far as I am aware, UVnovo is unique 
in this capability. So generated, the UVnovo fusion spectrum is currently used for de novo 
sequence predictions, though it could easily be transformed into a spectral representation 
optimized for use by standard database search algorithms such as SEQUEST and 
MaxQuant. 
Our methods for collection of paired CID/UVPD spectra and subsequent de novo 
interpretation offer potential improvements to serum antibody characterization. UVPD 
generates comprehensive precursor peptide fragmentation that manifests as a clean series 
of y fragment ions, and these characteristics make it ideal for de novo sequencing. This 
uniform fragmentation could improve CDR-H3 peptide spectra, especially at the N-
terminus where CID coverage is persistently poor. Such application could substantially 
reduce ambiguous PSM assignments and consequently improve our detection of CDR-H3 
peptides. This promises to improve our capabilities for sequence-guided repertoire 
proteomic studies, and with continued development, our methods may provide a means to 
identify at the very least, CDR-H3 peptide sequences de novo, and more ambitiously,  
serum monoclonal antibodies through proteomics alone.
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